Background: Levamisole is a synthetic compound used as an anthelmintic. It has been found in adulterated cocaine linked with ANCA associated vasculitis. Methods: This is the case of a 58-year-old male presented to accident and emergency with dysphasia. A stroke was suspected and an urgent CT head scan, demonstrated a lacunar infarct. He was commenced on aspirin 300mg, clopidogrel 75mg, lansoprazole 30mg, and Atorvastatin 40mg. His secondary risk factors included hypertension, obesity and a smoking history. Blood tests at the time of admission demonstrated stage three chronic kidney disease and protein and blood on urine dip. A full nephritic screen was performed. ANCA was positive in a cytoplasmic pattern, with a positive PR3 of 72U/ml. Urine demonstrated 122 red blood cells but no casts. There was an unfortunate delay of six weeks before renal review. A kidney biopsy was conducted which demonstrated advanced scarring of his kidneys with obsolete glomeruli, however there was still activity in one crescent. A diagnosis of C-ANCA positive renal vasculitis was given and he was commenced on Prednisolone 60mg and Adcal D3. An urgent referral to rheumatology was made for consideration for IV cyclophosphamide. The rheumatology consultation elicited a history of long-standing poor memory, which appears to have predated his stroke. His MRI subsequent to his stroke showed involvement of the left corona radiate, discrete focus on the right, with additional hyper-intense foci scattered within the white matter of both cerebral hemispheres. Review of CT and MRI scans demonstrated evidence of very significant paranasal sinus disease. There was some evidence of bony destruction including the medial orbital wall on the right and some thickening of the medial extra-ocular muscle. There was increased signal at the same site on the MRI. Surprisingly he denied any nasal symptoms. He admitted otherwise of some wheeze in the chest since the stroke but there were no other neurological symptoms, no hearing symptoms and he denied any constitutional symptoms. There was a history of DVT 4 years previously and a 10yr history of cocaine abuse up until the time of his stroke. He was diagnosed granulomatosis with polyangitis. The cocaine abuse we believe may have played a role in induction of his disease. Treatment plan currently is for 6 cycles of cyclophosphamide, reducing dose prednisolone with plans for Azathioprine as a DMARD in the future. Results: Differentiating between idiopathic vasculitis from drug and induced vasculitis can be challenging especially when serology is positive. ANCA positivity can be associated with both idiopathic and drug-induced vasculitis. Conclusion: This case highlights the need to take a thorough drug and social history. Despite review by several physicians the 10-year history of cocaine abuse was not elicited until 5 months after first contact. Disclosure statement: The authors have declared no conflicts of interest.
corneal grafting, and complications requiring evisceration of a blind and painful eye. Methods: The 3 patients described were seen in our local rheumatology department. They were diagnosed with corneal melt between April 2009 and June 2011. Results: Case 1: A 66 year old female with a 23 year history of rheumatoid arthritis, treated with oral methotrexate, presented with symptoms of dry eye, initially well-controlled with lubricating eye drops. She subsequently developed peripheral corneal ulceration requiring treatment with topical antibiotics and steroid. Early corneal melt was identified. Unfortunately, she developed bacterial keratitis and an abscess, leading to perforation and a large corneal defect. Tissue glue and a bandage contact lens were applied. The methotrexate dose was increased but she declined admission for IV methylprednisolone. 3 months later, the eye was painful, had lost light perception and bled frequently due to corneal vascularization. A decision was made to proceed with evisceration. Case 2: A 78 year old female with a 26 year history of rheumatoid arthritis, treated with oral methotrexate, had a left cataract extraction. One month later, a peripheral guttering ulcer developed. Despite topical steroid and chloramphenicol, within 2 months she had developed corneal melt. The methotrexate dose was increased. The corneal melt resolved but unfortunately recurred 3 months later. She was admitted for corneal tissue glue, crescentric tectonic corneal graft, amniotic membrane and bandage contact lens. Prednisolone 40mg daily was commenced, followed by intravenous methylprednisolone and cyclophosphamide infusions. The corneal graft healed well and the patient is now on oral methotrexate alone. Case 3: A 60 year old male with an 18 year history of rheumatoid arthritis, treated with sulfasalazine and subcutaneous methotrexate, developed irritation, redness and photophobia of both eyes. Inferior ulcers were diagnosed and treatment with topical steroids, antibiotics, acetylcysteine and lubricating drops plus oral prednisolone was commenced. 6 months later there was no evidence of active vasculitis so treatment focused on lubricating drops. Unfortunately, 11 months after the initial symptoms there was sudden progression to corneal melt. Sutures, a tissue glue patch and a bandage contact lens were applied. He subsequently developed bacterial keratitis and endophthalmitis, necessitating admission. The corneal melt stabilized with IV methylprednisolone infusions and an increased dose of methotrexate. A lamellar tectonic corneal graft was performed, followed by amniotic membrane graft. The graft healed well.
Conclusion: These cases demonstrate the management of severe peripheral ulcerative keratitis and corneal melt. Corneal melt is a rheumatological emergency and may require urgent immunosuppression. In all cases both systemic and topical treatment was required, although IV cyclophosphamide was required in one case. Disclosure statement: The authors have declared no conflicts of interest.
HEADACHE: NOT ALWAYS FIBROMYALGIA
Muhammad K. Nisar Rheumatology, Luton and Dunstable University Hospital, Luton, UNITED KINGDOM Background: Cupping treatment is getting popular in Western world as an alternative approach to treating various ailments including pain. Recent stories of various sports and media celebrities use of this modality has also helped set the trend. It is an ancient medical technique that is still in vogue in several contemporary societies particularly Middle East and China for the management of various pain syndromes. It has been part of Traditional Chinese Medicine for at least 2000 years. Although there is some evidence of its utility, data are inconsistent and the therapeutic effectiveness remains controversial. Methods: The following case highlights the hitherto unreported hazard associated with this, largely unregulated, treatment and emphasizes the need to explore use of alternative therapies in common rheumatology presentations such as headache. Results: A 32 year old previously well Asian lady was referred to the local rheumatology department having suffered with severe headache. Further questioning confirmed recurrent frontal headache for few months associated with stress unresponsive to simple analgesics. There were no red flags and the examination was normal. Provisional diagnosis of tension headache, in the context of fibromyalgia, was suggested however a CT scan of the head was scheduled in light of the nocturnal symptoms. The CT was normal and hence she was discharged back to her primary care physician. As the headache was not improving, she sought opinion from an alternative therapy provider who suggested cupping treatment. She underwent wet cupping on her scalp for two weeks with moderate improvement. Two weeks later she contacted the department with sudden worsening of headache with no neurological deficits. A routine MRI of the head and an appointment with neurologist were scheduled. Surprisingly, MRI scan showed bilateral acute subdural haemorrhage with mild mid-line shift. Previous CT scan was re-reviewed and the findings were certainly new. Urgent neurosurgical intervention ensued with evacuation of haematomas and full recovery. Both MR angiogram and venogram were unremarkable. An extensive set of investigations failed to show any bleeding disorder and hence patient was advised to avoid cupping treatment in future. Conclusion: To our knowledge, this is the first report of bilateral subdural haematomas induced by cupping therapy. There has been one reported case of haemorrhagic stroke after cupping for cervicalgia. The authors proposed plausible explanations including an acute rise in blood pressure, dissection of an existing intimal tear or microinclusions intensifying the local stress concentration of a cup. Another case suggested development of acquired haemophilia A associated with therapeutic cupping, although the mechanism for this complication remains elusive. In conclusion, vigilance is required to explore the history of all alternative therapies, especially cupping treatment, in patients presenting with pain disorders. Disclosure statement: The author has declared no conflict of interest.
CHIKUNGUNYA AND SPONDYLOARTHROPATHY: IS THERE AN ASSOCIATION?
Muhammad K. Nisar 1 and Christabel I. Packianathan 2 1 Rheumatology and 2 Acute Medicine, Luton and Dunstable University Hospital, Luton, UNITED KINGDOM Background: Chikungunya (CKG) is an arthritogenic mosquitotransmitted alphavirus that manifests itself as a febrile illness and often progresses to severe and incapacitating polyarthralgia. Several reports have demonstrated persistent polyarthritis akin to seronegative peripheral arthropathy. However, to our knowledge, imaging-confirmed axial disease has not been described in this context. Methods: We report the case of an Asian lady who developed axial spondyloarthropathy (SpA) after contracting CKG while visiting India during an outbreak. Results: A 51-year-old previously healthy woman developed CKG infection while traveling to India during a regional outbreak in an endemic area. It began with classic symptoms of acute fever and generalized myoarthralgia followed by residual pain primarily affecting the small joints and to a lesser extent, pain in the lumbar region and both hips. There was no family history of SpA. Initial investigations including inflammatory markers at the time were unremarkable. Dengue nonstructural protein 1 antigen and dengue IgM were negative. Thyroid function tests and bone profile were normal. Serum 25-OH vitamin D was within the reference range. X-rays of small joints at the time showed soft tissue swelling in the wrists and ankles. The X-ray of the lumbosacral spine showed minor degenerative change in L4/5 and L5/S1, whereas that of the sacroiliac joints was normal. The patient was commenced on regular non-steroidal antiinflammatory drugs (NSAIDs). Following graded physical activity over six months, her symptoms improved, apart from mild episodic fatigue and lethargy. A year later she presented to our rheumatology department with a 2-month history of severe intermittent alternating pain in both hips and buttocks. She experienced low back pain in addition to widespread myalgia, malaise and fatigue. Investigations at the time of presentation showed a normal full blood count, serum biochemistry, C-reactive protein, liver functions, glucose, bone profile including vitamin D, thyroid function, negative antinuclear antibody, anti-cyclic citrullinated protein antibody, rheumatoid factor, and human leukocyte antigen B27. Her CKG IgG was strongly positive (>1:10,000 by an indirect fluorescent antibody test). Surprisingly, the bone scan showed increased uptake in the inferior aspect of the sacroiliac joints bilaterally with the right joint involved more than the left. A magnetic resonance imaging (MRI) scan confirmed bilateral sacroiliitis with marked oedema across the inferior aspects of the joints. The patient was commenced on regular NSAIDs and physiotherapy with good symptomatic relief. Conclusion: There are numerous reports suggesting CKG arthritis can mimic rheumatoid arthritis. However, to our knowledge, this is the first report of CKG-associated axial SpA. As outbreaks of this debilitating disease become global, a high level of suspicion is required for early diagnosis and management, particularly in centers with little exposure to this disease. Disclosure statement: The authors have declared no conflicts of interest. Rheumatology, Basildon University Hospital, Essex, UNITED KINGDOM Background: We herein present two cases that demonstrate large vessel (LV) involvement in the context of ANCA-associated vasculitis (AAV). Are these two separate co-existing entities or a spectrum of the same disease? Methods: The first case, a 66 year old male diagnosed with classic features of Granulomatosis with polyangiitis (GPA) with pulmonary nodules, renal involvement and a PR3 >177. He responded well to corticosteroids, iv Cyclophosphamide and maintenance Azathioprine. He re-presented 4 months later with severe abdominal pain warranting a CT of the abdomen which demonstrated thickening of the aorta and innominate arteries. PET/CT confirmed the findings. He was placed on Rituximab and is now in remission. The second case is that of a 66 year old male who presented with jaw and tongue claudication, limb ischaemia, fleeting arthralgia and constitutional symptoms. CRP was 15, PR3 72. Giant cell arteritis (GCA) with large vessel involvement was suspected. Temporal artery biopsy gave the appearance typical of healing GCA. He was treated with IV corticosteroids and Azathioprine with good response. On weaning Corticosteroids, limb claudication symptoms ensued. IV Cyclophosphamide was administered along with weaning dose steroids. Several months later lung cavities were noted on CT scan which was performed for chest symptoms. Histology demonstrated necrotizing granulomas consistent with GPA and an aspergilloma within the cavity. Bronchial washing cultivated Aspergillus spp. He was treated with antifungals, antibiotics and later Rituximab. Despite remission, he continued to have respiratory symptoms related to lung cavitation. Results: Although very rare, large vessel involvement associated with GPA has been documented in case reports. Large vessel involvement can precede the development of or occur in the absence of small vessel vasculitis. It usually presents in the form of periaortitis, aortitis or Temporal arteritis. LV involvement in AAV often has a poor outcome with aortic dissection, rupture and stenosing arteries. This usually occurs in both MPO and PR3 subtypes. The epidemiologic, clinical and histological characteristics of these patients differ from those of the well-defined large vessel vasculitides such as GCA or Takayasu's arteritis. Biopsy is indicated to establish diagnosis. Small temporal artery branches and vasa vasorum involvement in GCA are common, however, frank finbrinoid necrosis is unusual in classical GCA and could be suggestive of systemic necrotizing vasculitis. Involvement of the posterior ciliary arteries, which are small branches of the ophthalmic artery resulting in anterior ischaemic optic neuropathy (AION) can occur in both. Conclusion: It is important to recognize that large vessel inflammation occurs in ANCA-associated vasculitides and is part of a spectrum of disease. It can precede or follow the classical manifestations of ANCA positive vasculitis and it seems to respond as well to B cell depletion. Disclosure statement: The authors have declared no conflicts of interest.
LARGE VESSEL INVOLVEMENT IN ANTI_NEUTROPHIL CYTOPLASMIC ANTIBODY-POSITIVE VASCULITIS

RECURRENT TESTICULAR PAIN PRECEDING THE MANIFESTATION OF MICROSCOPIC POLYANGIITIS
Matthew Chak Hin Szeto 1 and Samantha L. Ladd 2 1 Rheumatology Department and 2 General Internal Medicine, Maidstone Hospital, Maidstone, UNITED KINGDOM Background: Testicular involvement of systemic vasculitis is rare. It is most associated with Polyarteritis Nodosa (PAN) and is included as part of the American College of Rheumatology Classification criteria for PAN, although there are case reports describing testicular involvement in other systemic vasculitides, such as Henoch-Schö nlein purpura (HSP) and Granulomatosis with Polyangiitis (GPA). Urogenital manifestation is not listed in Birmingham Vasculitis Activity Score; therefore, clinicians may under-recognize urogenital symptoms as a manifestation of non-PAN vasculitides. Methods: A 46 years old man presented with a 5 weeks history of worsening chest pain, characteristic of pericarditis. His echocardiogram revealed impending tamponade secondary to a large pericardial effusion, which was successfully drained. C-Reactive Protein was elevated at 236mg/L. He developed an acute kidney injury, with creatinine rise from the baseline of 65 mmol/L to 150 mmol/L. Urine protein:creatinine ratio was 269 mg/mmol and microscopy found >100 red cells/mm 3 . On further questioning, the patient reported 10 kg weight loss in the last 5 months. He also reported 3 episodes of left testicular pain and swelling in last 6 months which were treated as presumed infective epididymo-orchitis. An ultrasound of his testes was arranged on the third presentation.
Results: On review of testicular ultrasound, there was abnormal echotexture and heterogeneous testicular parenchyma at the upper pole of the left testis. Vascular Doppler signal was reduced in the upper pole. This was atypical for infective epididymo-orchitis, and a partial infarction secondary to vasculitis was suspected. The patient was further investigated for possible PAN. CT angiogram of mesenteric and renal arteries was normal. Viral serology for Hepatitis B, Hepatitis C and HIV were negative. Anti-Neutrophil Cytoplasmic Antibody (ANCA) was positive with a pANCA pattern. Anti-Myeloperoxidase antibody was significantly elevated at 76.2U/ml. Pericardial fluid analysis was compatible an inflammatory exudate. Renal biopsy showed a pauciimmune glomerulonephritis. Based on the above, a diagnosis of Microscopic Polyangiitis (MPA) was made.
Conclusion: This gentleman has recurrent testicular symptoms preceding his diagnosis of MPA. Testicular involvement in MPA is very rare, with only 1 previous case report describing this association. There may be under-reporting in older case reports as MPA was not distinguished from PAN until the 1994 Chapel Hill Conference. Several published cases reported reduced vascular Doppler signal as a feature of testicular vasculitis. This finding should therefore trigger consideration of vasculitis, especially in patients with recurrent or persistent symptoms. The main differential is testicular torsion, which is extremely rare in adult over 30 years old. Some testicular tumours also have reduced vascularity, but a mass is usually visible on ultrasound examination. Our case is a reminder that testicular involvement is not limited to PAN, but can occur in many systemic vasculitides. In assessment of patients with systemic vasculitides, clinicians should ask about urogenital symptoms, as these are often not volunteered by patients. Disclosure statement: The authors have declared no conflicts of interest.
A CASE OF HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, THE GREAT MIMICKER OF RHEUMATIC ILLNESS
Oseme T. Etomi, Angela Pakozdi and Hasan Tahir Rheumatology, Whipps Cross University Hospital, London, UNITED KINGDOM Background: HLH is a rare and life-threatening condition characterized by persistent fever, hepatosplenomegaly, pancytopenia, lymphadenopathy and rash. It can be described as a syndrome of overwhelming auto-inflammatory response often driven by an underlying genetic predisposition, common infective triggers, haematological malignancies and rheumatological diseases (mainly AOSD and SLE). There are many similarities between HLH and ASOD. Given the significant morbidity and mortality attached to this diagnosis, it makes it an important differential diagnosis to consider when approaching a patient with pyrexia of unknown origin. Methods: A 57-year-old man presented via Accident and Emergency with a twelve-day history of fevers, night sweats and rigors. He reported symptoms of a dry non-productive cough. His past medical history included a history of hypertension, type 2 diabetes and recurrent episodes of pneumonia. He was originally from British Guyana, but had lived in the UK since the age of 4. There was no history of foreign travel or unwell contacts. Physical examination revealed widespread lymphadenopathy.
Results: Blood tests revealed pancytopenia (Hb 126, MCV WC 0.8, Plt 139), abnormal liver function (Bilirubin 27, ALT 114, AST 373, GGT 401) and a CRP of 304. He was treated for neutropenic sepsis and further tests arranged. Immunoglobulin screen detected a pan-hypogammaglobulinaemia. LDH 2,000, Ferritin 30,000 and triglyceride of 7. Virology screen was negative. CT of the chest, abdomen and pelvis showed prominent lymphadenopathy in the axillae but no organomegaly. Urinalysis was normal. At this point, a bone marrow biopsy and lymph node examination were performed to exclude a haematological diagnosis which showed a grade 3 fibrosis with no features of malignancy. Multiple blood cultures were sent and one bottle isolated a fully sensitive Enterococcus. An echocardiogram showed suspicious vegetation on the mitral valve. The possibility of infective endocarditis was raised and broad spectrum antibiotics were started. Despite broad spectrum antibiotics, high-grade fevers persisted, with progressively worsening pancytopenia, rising inflammatory markers, ferritin and LDH as well as a progressive coagulopathy. The mitral vegetation's were felt to be marantic. In the absence of a diagnosis, a review of all histology was requested and a liver biopsy was scheduled. A soluble CD25 was also sent. Intravenous immunoglobulin was commenced for a suspected diagnosis of HLH and hypogammaglobulinaemia. Unfortunately the patient died soon after the liver biopsy. A review of the histology revealed a diagnosis of a high grade B Cell Lymphoma and the CD25 confirmed the diagnosis of HLH. Conclusion: HLH is an important cause to be considered when reviewing a patient with a PUO. If the clinical picture doesn't fit or the symptoms do not abate on standard treatment, it is important to review all previous information and continue the search for the underlying diagnosis. Disclosure statement: The authors have declared no conflicts of interest.
HOW TO DIAGNOSE AND MANAGE SEROSITIS: AN EVIDENCE-BASED PARADIGM
Clive Kelly, Emma Fisken and Manisha Ahuja Medicine, Queen Elizabeth Hospital, Gateshead, UNITED KINGDOM Background: Inflammation of the pleura, pericardium or peritoneum is recognized as serositis. This is often associated with systemic illness and pyrexia. It can be precipitated by infection and patients may be treated empirically with antibiotics. However, inflammatory disorders may also present in this way, particularly when more than one organ is involved.
METHODS:
We have summarized case histories of four patients each of whom presented with serositis and in whom infection was excluded. Each case was due to different diseases and required very different treatment.
RESULTS:
The first patient had abdominal pain with ascites and a history of surgery for previous aseptic peritonitis. Urinary porphobilinogen was positive and she required treatment with HaemArginate for acute intermittent porphyria. The second patient presented breathless with fever and arthralgia. She had pleuropericardial effusions, positive ANA and antiphospholipid antibodies. She required rituximab for systemic lupus erythematosus. The third patient presented with arthralgia, multiorgan failure and serositis. Her evanescent rash and high ferritin supported our clinical diagnosis of Adult onset Still's disease. She received IV cyclophosphamide and methylprednisone, followed by oral immunosuppressives, to good effect. Our final patient had a history of recurrent pyrexia, myalgia and generalized pain affecting her chest and abdomen, with intracavitary effusions. She had undergone multiple inconclusive investigations but had a family history of similar presentations. She was successfully treated with colchicine for periodic fever syndrome. Conclusion: Serositis may be overlooked or undervalued in patients with recurrent thoracic or abdominal pain. There are a broad range of conditions that may present in this way and we have developed a diagnostic flow chart to guide clinicians in the diagnosis and management of these relatively rare but sometimes life threatening disorders. Disclosure statement: The authors have declared no conflicts of interest.
A CURIOUS CASE OF ABDOMINAL PAIN: IGG4-RELATED PERIAORTITIS
Rameez Arif
Medicine, Rheumatology, Luton & Dunstable Hospital, Luton, United Kingdom
Background: A 46 year old gentleman of Bangladeshi origin presented to the Emergency Department with a 3 week history of bilateral Loin pain, worse in the left Loin. Methods: Clinical examination elicited left renal angle tenderness. The abdomen was otherwise soft with no signs of peritonism. The clinical impression initially was that of renal calculi and pyelonephritis; however it was noted that there were atypical features against either diagnosis. He proceeded to have a CT of the abdomen with contrast, which showed a soft tissue density thickening along the left posterolateral margin of the descending aorta. This was radiologically suspected to represent acute left infra-renal Peri-aortitis, which would account for the patient's symptoms. A subsequent PET/CT confirmed increased activity in the aortic soft tissue. The patient had significantly raised ESR and CRP. In addition IgG4 serology was performed and was strongly positive. Upon review by the Rheumatology team the patient was commenced on oral steroids and low dose azathioprine with dramatic improvement in his symptoms within 2-3 days. He was diagnosed with IgG4-related Peri-aortitis.
Results: The patient has since been followed up in rheumatology outpatients, with gradual tapering of his immunosuppressants, and regular review of symptoms and clinical condition. Conclusion: IgG4-related disease has recently been documented and acknowledged as a clinical entity since early 2000. Since then further cases of IgG4 disease have been described, however the diagnosis remains rare. IgG4-related disease is an immune-mediated condition characterized by a Lymphoplasmacytic infiltrates enriched in IgG4 plasma cells, affecting various different organs. Clinical features can vary considerably, depending on the organ involved. Commonly IgG4-related disease can cause autoimmune pancreatitis, Retroperitoneal Fibrosis, Aortitis or Peri-aortitis, Thyroid disease, Lung and pleural disease, and IgG4-related sclerosing cholangitis. Peri-aortitis classically presents with dull abdominal and flank pain of insidious onset. Systemic features such as fever, weight loss, malaise and vomiting may also be present. There are limited data on the natural history of the disease. Typically, patients display a fast recovery with immunosuppressants; however relapses are common with discontinuation of therapy. The current recommendations for treatment is prednisolone 40mg/day. Disclosure statement: The author has declared no conflicts of interest. Background: This 52 year old female presented in January 2016 to the hepatobiliary surgical team with anorexia, weight loss, jaundice and elevated liver function tests. MRCP showed dilatation of the biliary and pancreatic ducts with subsequent ERCP confirmation of narrowing of the common bile duct and negative for any malignancy. The common bile duct was stented and patient was diagnosed and managed as a probable autoimmune pancreatitis with oral steroid with good effect.
GRANULOMATOSIS WITH POLYANGIITIS PRESENTING AS AUTOIMMUNE PANCREATITIS
Weaning of steroid proved difficult due to return of symptomatology and a diagnosis of steroid induced diabetes was also made. In August 2016, progressive shortness of breath on exertion, non-productive cough and right sided pleuritic chest pain resulted in re-presentation to hospital. Chest X-ray showed a right sided pleural effusion with collapse and consolidation and antibiotic therapy was commenced. Due to no real improvement with antibiotic therapy a CT scan of the chest was performed showing similar findings to the chest X-ray, but in addition showed a number of small lung nodules and a differential of metastasis was considered. Histology from CT guided biopsy showed evidence of necrotizing granulomatous inflammation. ANCA screening subsequently showed a C-ANCA of 80 and a PR3 >8 suggesting a diagnosis of granulomatosis with polyangiitis. In addition to chest pathology a urinalysis showed þþþ blood and þþþ protein with normal renal function in keeping with probable renal involvement. Results: On review in rheumatology clinic the patient had features suggesting pulmonary and renal involvement as well as bilateral episcleritis, peripheral neuropathy, vasculitic rash on lower limbs and arthralgia/myalgia. With recent investigation results available, treatment was initiated with oral prednisolone 60mg and patient counselled for treatment with intravenous cyclophosphamide. Steroid therapy made a dramatic improvement to symptoms with rapid fall of CRP from 250mg/L to normal within a few weeks. Unfortunately as treatment with cyclophosphamide got under way, renal function also deteriorated with estimated glomerular filtration rate falling to 8ml/min and creatinine climbing to 482 mmol/L. Under the careful watch of the renal physicians, cyclophosphamide was continued and after 2 weeks, renal function slowly improved and plasma exchange was narrowly avoided. Cyclophosphamide and reducing steroid therapy is ongoing and the patient is progressing well. Conclusion: This case is interesting as although the respiratory and renal involvement are classical presentations of granulomatosis with polyangiitis, in retrospect the admission to hospital 6 months prior with autoimmune pancreatitis was likely an unrecognized feature of this patient's evolving ANCA associated vasculitis. Investigation of pancreatitis leading to a diagnosis of granulomatosis with polyangiitis is rare but is recorded in the literature with a number of case reports. It highlights the need to be vigilant for underlying ANCA-associated vasculidities in patients presenting with pancreatitis of unclear aetiology. Disclosure statement: The authors have declared no conflicts of interest.
A RARE CAUSE OF JOINT PAIN
Iman Ali and Wahab Al-Allaf Rheumatology, Royal Wolverhampton Hospital, Wolverhampton, UNITED KINGDOM Background: Joint pain is a common manifestation in rheumatology.
Establishing an underlying cause is not always straightforward and can be challenging. Methods: We report the case of a young female patient who presented with joint pain and found to have hereditary angioedema. Results: A 28-year-old Caucasian lady with no significant past medical or family history. Presented to rheumatology department with 10 year history of intermittent multiple joints pain mainly involving her knees, small joints of her hands and the wrist. A typical episode include, one joint will be affected at a time; with gradual onset occurring over few hours and lasting for up to three days associated with swelling and tenderness of the affected joint and later the appearance of skin rashes. Physical examination was generally unremarkable. Routine blood tests demonstrated raised CRP, normal ESR and negative rheumatoid factor and Anti-CCP (Table 1) . Initial clinical suspicion was in favour of palindromic rheumatism. In addition to that, she kept complaining of long standing recurrent severe and disabling abdominal pain associated with vomiting. A series of investigations by gastroenterologist failed to establish a convincing diagnosis. A CT scan of her abdomen and an upper gastrointestinal endoscopy examination revealed no significant abnormalities. The gastroenterologist felt that her symptoms were due to functional rather than organic disorder. However, she was considered for cholecystectomy at a later stage. While being assessed in rheumatology department and based on her unusual presentation and continued symptoms, hereditary angioedema was suspected which was later confirmed during C1 Esterase inhibitor and complement levels assessment. The patient is now being treated for this condition and cared for jointly by multidisciplinary team of a rheumatologist and an immunologist in order to provide her with evidence based treatment.
012 Results: The first case is that of a 20 year-old man who at age 4 was diagnosed with chronic recurrent multi-focal osteomyelitis affecting L1-L2 vertebrae. At age 9 he had an episode of aseptic multiphasic disseminating encephalomyelitis. Genetic testing revealed single mutation for c.2282G>A(p.Arg761His) in the MEFV gene. During the course of his illness the patient was treated with corticosteroids and (in sequence): adalimumab (40mg/15days), colchicine (2g/day), mycophenolate (2g/day), hydoxychloroquine (400mg/day). Despite treatment, he had persisting normocytic anemia (Hb 10g/dL) and high acute phase response (CRP 100mg/L, normal<5; amyloid levels 200, normal<30). A trial of anakinra only resulted in partial clinical response, leading to a tocilizumab trial. This resulted in rapid and sustained clinical/biochemical improvement. The second case is that of an 18 year-old man who at age 9 was diagnosed with aseptic meningoencephalitis necessitating high dose glucocorticoids. He had persisting pyrexia and anemia with negative microbiological tests. Azathioprine and rituximab were unsuccessful, but there was good clinical response to sirolimus (rapamycin), the latter discontinued after two years. Following a relapse of fevers and also headaches, a diagnosis of meningoencephalitis was made CSF analysis and microbiological tests were unremarkable. The patient received corticosteroids (1g/day over 3 days) resulting in rapid symptom resolution. Genetic testing revealed heterozygosity for the c.2177T>C(p.Val726Ala) of the MEFV gene. Reintroduction of sirolimus was unsuccessful, leading to a trial of tocilizumab (8mg/kg sc/week), which enabled steroid withdrawal. Conclusion: Both these patients share similar clinical and genetic characteristics. Pyrexia and CNS involvement were key features and treatment response was best sustained with IL-6 inhibition, suggesting a high IL-6 drive. The clinical picture and response to treatment was atypical for FMF, posing significant diagnostic challenges. The possibility of digenic inheritance in autoinflammation-associated genes was considered but ruled out in both patients, who were negative for NLRP3, TNFRSF1A and MVK genes. Whether the single identified FMF mutation at least partly accounts for the abovedescribed clinical pictures remains speculative. The role of epigenetics and/or environmental factors in triggering disease in geneticallypredisposed individuals and the clinical impact of single gene mutations in autosomal recessive disease represents an exciting area. We hope through these cases to highlight the complexity of autoinflammatory disease and provide further insights into mechanistic pathways involved. Disclosure statement: The authors have declared no conflicts of interest. Background: Primary angiitis of the central nervous system is a rare type of cerebral vasculitis which only affects the central nervous system. It has an incidence of 1-2 per million population compared with 40 per million population for systemic vasculitis. Methods: We present a 41 year old Caucasian female admitted with right-sided weakness which was associated with bilateral paraesthesia and blurred vision. There was no significant medical or medication history, or illicit drug abuse. On examination she had severe rightsided weakness and sensory deficit. Blood tests including inflammatory markers, ECG, chest X-ray and CT of the brain were all unremarkable. A subsequent diffusion-weight MRI of the brain demonstrated multiple acute infarcts affecting the frontal and parietal lobes, especially on the left side. A simultaneous MR-angiogram noted multiple strictures in the right internal carotid artery and circle of Willis with appearances suggestive of vasculitis. This was confirmed on CTangiogram. Virology screen, Lyme disease serology, TB-antigen and autoimmune screen including ANCA and ANA were all negative. A transthoracic echocardiogram was also normal. A lumbar puncture was unremarkable except for marked protein levels (0.81 g/l). Within 24-hours of admission the patient developed confusion, worsening right-sided weakness and expressive dysphasia despite high-dose aspirin. She was therefore commenced on high-dose prednisolone 60 mg but later switched to intravenous methylprednisolone 1 g, as her neurological signs continued to deteriorate. Despite steroid treatment her neurology continued to fluctuate from complete resolution to paralysis. She was therefore commenced on intravenous cyclophosphamide 750 mg. Gradually, with immunosuppressant treatment as well as multidisciplinary rehabilitation her weakness improved and her confusion and dysphasia resolved. She underwent six cycles of cyclophosphamide treatment and will commence azathioprine as maintenance. Results: The patient was discussed between the neurology, rheumatology, neuroradiology and neurosurgical teams. All were in agreement that her symptoms were consistent with cerebral vasculitis. Despite extensive investigations, there was no evidence of systemic vasculitis. She was therefore diagnosed with primary angiitis of the central nervous system. Although a biopsy would confirm the diagnosis, this was not pursued given her presentation, imaging findings and excellent response to immunosuppressive treatment. Conclusion: Rheumatological disease such as vasculitis should be considered in any patient presenting with stroke at a young age. Vasculitis is typically a multi-systemic disease which can be associated with raised serum inflammatory markers and positive serum ANCA. However, it rarely can exclusively affect the brain and spinal cord and can only be diagnosed through lumbar puncture, imaging techniques and biopsy. Finally, inflammatory conditions such as vasculitis, SLE and rheumatoid arthritis are associated with increased risk of ischaemic heart disease and stroke. Appropriate management of these rheumatological conditions is therefore essential in preventing cardiovascular disease. Disclosure statement: The authors have declared no conflicts of interest.
A RARE CAUSE OF STROKE: PRIMARY ANGIITIS OF THE CENTRAL NERVOUS SYSTEM
WHEN UROLOGY MEETS RHEUMATOLOGY: IGG4-RELATED DISEASE AS A RARE CAUSE OF RETROPERITONEAL FIBROSIS AND PERIAORTITIS
Claudia Worth, Hilary Johnson and Elaine C. Smith Rheumatology, Cheltenham General Hospital, Cheltenham, UNITED KINGDOM Background: IgG4-related disease is a chronic fibroinflammatory condition characterized by serum IgG4 elevation and tissue infiltration with IgG4 positive plasma cells. This can lead to pseudotumours and affect almost every organ. We report a case of a retroperitoneal fibrosis secondary to IgG4-related disease that illustrates the challenges in diagnosing and treating this rare condition. Methods: A previously well 51 year old woman presented with a three month history of left sided loin pain and intermittent fevers and sweats. She was not taking any regular medication apart from bimatoprost eye drops for ocular hypertension. Physical examination showed left renal angle tenderness and an aortic murmur. Results: The initial laboratory findings showed an elevated acute phase response (CRP 156 mg/l and ESR 32 mm/hr) and mild deterioration in renal function with a reduction of eGFR to 42 ml/min from a baseline of 80 ml/min. Echocardiography was normal. CT imaging of her abdomen showed a subcapsular fluid collection around the left kidney and extensive retroperitoneal fibrosis with marked paraaortic soft tissue infiltration. Left ureteric obstruction led to subsequent perforation of the renal calyx into the pararenal tissues. Following urgent urological consultation a left retrograde JJ stent was placed with excellent symptomatic improvement. A review of the patient's history did not reveal any risk factors or precipitating medications for the development of retroperitoneal fibrosis. There was a possible risk of occupational exposure to TB. TB testing was subsequently negative. LDH was normal and immunology was negative for ANA and ANCA. Serum immunoglobulin levels were normal with a normal IgG4 subclass level of 0.88 g/L. PET/CT imaging confirmed extensive retroperitoneal fibrosis but did not show any evidence of malignancy, vasculitis or aortitis. Biopsy was arranged despite technical difficulty due to the anatomical site of the fibrosis. Histology showed fibrous connective tissue with aggregates of inflammatory cells with prominent plasma cells. Immunohistochemistry revealed strong cytoplasmic staining for IgG4 in at least half of the plasma cells present. She was commenced on 30mg of prednisolone daily with a slow weaning regime. Methotrexate was started at 15mg weekly. This led to a rapid reduction of her CRP to 6mg/l and complete resolution of symptoms. Follow up CT imaging is pending. Conclusion: IgG4-related disease is a complex multisystem condition that responds well to immunosuppressive therapy commonly used by rheumatologists. Retroperitoneal fibrosis and para-aortic infiltration are hallmarks of the disease. High clinical suspicion for IgG4-related disease is needed and requires tissue histology with specialist staining for IgG4; especially as serum IgG4 levels may be normal. The pathophysiology of IgG4 related disease remains incompletely understood. Further research is needed to evaluate underlying disease mechanisms as well as possible immunomodulatory treatment options such as rituximab therapy. Disclosure statement: The authors have declared no conflicts of interest.
OCULAR INFLAMMATION: ONE OF MANY MANIFESTATIONS OF IGG4-RELATED DISEASE
Geetha Lakshmi Janakiraman and Muddassir Shaikh Department of Rheumatology, Freeman Royal Hospital, Newcastle upon Tyne, UNITED KINGDOM Background: IgG4-related disease (IgG4-RD) is an emerging immunemediated disorder linking many fibro inflammatory conditions previously considered as different entities. Middle-aged and elderly individuals, particularly men, are most commonly affected. Methods: We present an interesting case of a 66 years old gentleman who presented with intermittent aches in the right eye with lower eyelid swelling and proptosis to Ophthalmology. An inferior orbital lesion surrounding the inferior orbital muscle was discovered on CT of the orbit. He was treated with Prednisolone 40 mg reducing course over 2 months for idiopathic inflammatory diseases on orbital biopsy with initial good response. A year later he presented with slight increase in the proptosis and right lower lid puffiness. MRI revealed recurrence of orbital inflammation with proptosis. Methotrexate was commenced under Rheumatology as a steroid sparing agent. He had initial good response with systemic improvement and objective resolution of soft tissue inflammation around the eye with decreasing proptosis. However 6 months into commencement of Methotrexate he had worsening of symptoms. MRI revealed increasing muscle involvement, notably lateral inferior orbital nerve involvement which is suggestive of IgG4 disease. Review of previous histology from biopsy two year ago, revealed numerous IgG secreting plasma cells with majority of them IgG4 positive consistent with the diagnosis of IgG4-RD. The serum IgG4 levels were raised at 1.74 g/l. There was no other organ involvement or systemic features of vasculitis on CT of the chest, abdomen and pelvis followed by a PET scan. Subsequently he could not tolerate azathioprine due to side effects and he will be receiving Rituximab treatment soon. Results: IgG4-RD can affect a number of organs; most commonly involved organs are the submandibular glands (28%), lymph nodes (27%), orbits (22%), pancreas (19%) and retroperitoneum (18%). The serum level of IgG4 can be elevated, although nearly half of the patients with biopsy-proven, clinically active IgG4-RD have normal serum IgG4 concentrations. Elevations in the serum IgG4 concentration can suggest a subset of patients with a more severe disease phenotype. Glucocorticoids (GC) are usually used as the first line treatment. A study revealed 86% of patients showed improvement following treatment with GCs, although 77% did not achieve stable disease remission following GC treatment. Steroid-sparing agents and Rituximab has been used in patients not respond to GCs. Conclusion: Orbital myositis is one of the many manifestations of IgG4-RD. Early clinical index of suspicion is required to specifically look for this condition on biopsy specimens. Disclosure statement: The authors have declared no conflicts of interest. Unfortunately, no formal diagnosis was made as symptoms were thought be to non-specific. He denied any neurological features, history of DVT and joint swelling. General examination was unremarkable with no joint inflammation or active ulcers and no skin involvement was detected. Right eye examination showed acute hypopyon uveitis, retinal vasculitis along with macular infarct, with vision reduced to 3/60. There was no ocular inflammation in his left eye.
AN UNUSUAL CASE OF LUPUS TUBULOINTERSTITIAL NEPHRITIS WITH ACUTE KIDNEY INJURY
Results: The blood tests showed elevated CRP and ESR levels which had been elevated for years with no cause identified previously. Blood cultures were negative. HIV, syphilis serology, hepatitis screen, ANA and ANCA levels were negative and urine dipstick was normal. Based on his history and clinical findings a diagnosis of Behç et's disease was made and his care was co-managed by both ophthalmologists and rheumatologists. He was given IV methylprednisolone 10mg/kg, followed by reducing course of oral prednisolone and azathioprine. Due to significant eye involvement, Infliximab was considered which was given on day 9 at dose of 5 mg/kg following discussion and funding approval from National Behç et's Centre in Liverpool. 2 weeks after receiving infliximab, his vision had significantly improved. He has not had any further skin rashes or ulcers. Both fatigue and flu-like symptoms he suffered from for years had completely settled within days along with normalization of CRP level. Background: Quadriceps tendon impingement has been described as an inflammatory process within the anterior suprapatellar fat and is a potential cause for anterior knee pain. It is diagnosed by MRI as a mass effect on quadriceps tendon. Methods: A 63-year-old female was referred to musculoskeletal ultrasound (US) clinic with history of right anterior knee pain of three year duration, which was increasing during the past four months. The pain was exacerbated by daily activities and relieved by rest. No history of major trauma, fracture or infection. The patient had history of Type 2 diabetes mellitus and hypertension. She had limited improvement with medical treatment and physical therapy. Results: The right knee showed swelling and tenderness over the quadriceps tendon and the range of motion showed flexion 1108 which was painful beyond 308 and extension was full but painful during the last 108. Plain X-ray anteroposterior (AP) and lateral views showed grade III osteoarthritis with a big osteophyte at the anterior aspect of femoral condyle. US imaging showed mild synovitis with effusion. Sonopalpation revealed tenderness and reproduction of patients symptoms. Dynamic US imaging of the right knee clearly demonstrated the impingement of the quadriceps tendon by the anterior osteophyte during flexion and extension of the right knee. Conclusion: To our knowledge, this is the first case using dynamic US imaging to report quadriceps tendon impingement due to an osteophyte. We highlight the role of US in such cases, especially if the findings on the screen are coupled with reproduction of the patient's symptoms. Results: A 52-year-old male with a background of type two diabetes mellitus, hypertension and hypercholesterolaemia who had been taking simvastatin for 10 years presented with a six week history of myalgia and progressive muscle weakness. This weakness initially affected the proximal upper limbs and progressed to the proximal lower limbs. He denied any arthralgias, fevers, rashes, dyspnoea or dysphagia and had not started any new medicines that interacted with statins. On examination he was unable to stand from a seated position, there was reduced muscle power in the legs (3-4/5) and arms (4/5). Initial investigations revealed a WCC of 7.1 (Â 10 9 /l), CRP 30 mg/l, ESR 60 mm/hr, ANA was negative and the CK was 20 390 U/l; previously 93 U/l in 2013. MRI of the thighs demonstrated bilateral symmetrical oedema of the musculature consistent with myositis. EMG showed prominent fibrillation potentials and reduced action potential amplitudes in keeping with a generalized myopathic process. Muscle biopsy revealed little inflammatory response with macrophage activity and muscle fibre necrosis consistent with necrotizing autoimmune myopathy/myositis. The patient also had myositis specific antibodies in the form of antibodies against 3-hydroxy-3-methylglutarylcoenzyme-A reductase (HMGCR). After stopping the statin, 30mg of prednisolone daily was started with pulsed IV cyclophosphamide dosed at 15mg/kg given temporally according to the CYCLOPS regimen at 0, 2, 4, 7, 10 and 13 weeks. After 6 infusions of cyclophosphamide and a tapering course of prednisolone he was independently mobile with normal power in all limbs and a CK of 525 U/l. He was switched to methotrexate for maintenance immunosuppression. Conclusion: Anti-HMGCR positive statin induced autoimmune myositis is a rare cause of myopathy in statin exposed patients and may occur at any point during statin exposure. This diagnosis should be considered when there is proximal muscle weakness, a raised CK (>10,000) and a negative ANA. Muscle biopsy and myositis specific antibodies are important to support the diagnosis. Management can be difficult with symptoms continuing beyond cessation of statin treatment with different combinations of immunosuppressants required to control the disease. However, she re-presented 3 months later, after her prednisolone was reduced, with recurrence of headache, eye symptoms, diplopia, high ESR (96) and CRP (128). At this point she had developed jaw pain, worse on chewing and scalp tenderness. Biopsies showed focal infiltration of the adventitia by inflammatory cells extending through the media with disruption of internal elastic lamina, consistent with GCA. She was treated with 60mg of prednisolone and methotrexate. However, her headache persisted, with high inflammatory markers. MRI of the brain showed no signs of meningial enhancement. Patient had a mildly positive ANCA, but repeat was negative. In 2009 she was started on IV methylprednisolone and IV cyclophosphamide followed by methotrexate. This produced significant improvement in her symptoms. In 2014 methotrexate was discontinued because of suspected lung fibrosis. In 2016 she re-presented with myalgia, worsening arthralgia, weight loss and numbess of the left foot and a marked increase in inflammatory markers. 2: A 77 year old lady presented with classical GCA-like symptoms of temporal headache, scalp tenderness and features of PMR. TAB was reported as consistent with active giant cell arteritis. She responded well to highdose steroids but 2 years later, while on a very low dose of steroids started to get redness and pain in the left eye suggestive of sectorial scleritis usually seen in ANCA vasculitis. Results: Case 1: Repeat blood test showed a strongly positive MPO titre of 44. There was no active urinary sediments and her RFT was normal. A diagnosis of MPA was considered at this point and she was treated with further IV cyclophosphamide. Unfortunately her inflammatory markers flared again despite cyclophosphamide. She has therefore been commenced on Rituximab with very good results. Case 2: MPO titre came back strongly positive (>135), suggesting MPA. Symptoms improved with higher dose of steroids. Conclusion: Microscpic polyangiitis is well known to cause necrotizing inflammatory changes in the temporal artery mimicking GCA. However the progression of the disease especially in the second case suggests the appearence of medium or small vessel vasculitis in a patient with pre-exisiting GCA. This suggests an evolution in the condition's natural history although could also be coincidental. We need careful and uniform reporting of temporal artery histopathology to avoid diagnostic pitfalls. Biopsy-positive GCA patients should be carefully monitired to look for any features of other systemic vasculitis developing especially during the withdrawal of their immunosuppressive medications. Background: Granulomatosis with polyangiitis (GPA) is an ANCApositive vasculitis with diverse manifestations resulting in devastating sequelae if left undiagnosed. Classically it affects small to mediumsized vessels but rarely can affect large vessels. Inflammatory breast parenchymal lesions associated with GPA are uncommon. We present an atypical case of GPA with areolar breast inflammation, large vessel vasculitis and extra-ocular disease. Methods: A 41-year-old female presented with a 2 month history of a necrotic areolar breast lesion without systemic symptoms. Ultrasound guided biopsy revealed features consistent with pyoderma gangrenosum and secondary vasculitis. She was treated with high dose corticosteroids and ciclosporin. She was readmitted 1 month later with fatigue, decline in visual acuity and right eye proptosis. MRI revealed a right orbital granulomatous mass displacing the optic nerve. CT scan of the chest, abdomen and pelvis demonstrated further destruction of the right breast with evidence of aortitis and bibasal ground-glass pneumonitis. On serial monitoring, renal function and urine dipstick remained normal. Immunology showed PR3 ANCA positivity and with this evolving clinical picture a diagnosis of GPA was postulated. Induction therapy with pulsed IV methylprednisolone and eight cycles of cyclophosphamide was given, followed by maintenance therapy with Azathioprine and oral corticosteroids. CT imaging at 3 months revealed resolution of the right breast lesion, aortitis and pneumonitis without significant change in the extra-orbital inflammation. The patient was readmitted 2 months later with rapidly progressive extra-orbital inflammation and severe proptosis. She received further IV and oral corticosteroids followed by rituximab therapy which has been partially efficacious. Results: To our knowledge, we present the first ever case of GPA involving the highly unusual combination of areolar breast inflammation, large vessel vasculitis and treatment refractory extra-ocular disease. The unifying diagnosis of GPA was established due to the serological PR3 positivity and combination of eye, sinus and lung involvement. Breast tissue involvement has been identified in only 40 GPA cases. Lesions are usually single or multiple nodules, with fewer reports of skin ulceration affecting the breast parenchyma. The distinctive finding in our case is that the inflammation was localized to the areolar tissue. Aortitis is not part of the diagnostic nomenclature of GPA but rarely has been described with potentially life threatening consequences. Extra-ocular involvement can be refractory to traditional treatment and is associated with high rates of visual impairment. Limited evidence suggests partial efficacy to rituximab therapy. Conclusion: This case report illustrates an odd progression of GPA with large vessel vasculitis heralded by pyoderma gangrenosum of the breast and subsequent extra-ocular disease refractory to conventional treatment. This highlights the complexity and therapeutic challenges of GPA for the rheumatologist. One therefore needs to have an open mind and be vigilant to incongruous presentations of ANCA vasculitis. Disclosure statement: The authors have declared no conflicts of interest.
ANOTHER SITUATION WERE RHEUMATOLOGISTS CANNOT TRUST A CHEST X-RAY
Julie Dawson, Nabile Mohsin and Jennifer Christie Rheumatology, St Helens and Knowlsey Teaching Hospitals NHS Trust, St Helens, UNITED KINGDOM Background: A 65 year old woman presented with a 4 month history of early morning stiffness lasting 20 minutes and pain affecting her hands and feet. She had noticed her PIP joints were swollen. She had lost a few pounds in weight unintentionally but had no night sweats or other focal symptoms. She was an ex-smoker with a 25 year pack history. On examination she was found to have noticeable finger clubbing and tender left PIP joints, but no clear synovitis. Chest examination was normal. Her CRP was 34 mg/l, ESR 25 mm/h, RF negative and anti-CCP also negative. The X-ray of the hands was reported as showing a periosteal reaction in the distal ulnar and radius. Feet showed degenerative change and the chest X-ray was normal. The US showed minimal vascularity in the wrist joint; suggestive of mild synovitis and synovial thickening in two MCP joints. Methods: Symptoms and signs progressed with clinically evident synovitis in 4 joints as well as marked finger clubbing. When questioned she had noticed a dry cough for several months. There was no breathlessness or haemoptysis. Her CRP had now increased to 61mg/l. A diagnosis of hypertrophic pulmonary osteoarthropathy (HPOA) was suspected. A CT of the chest was requested and this showed a 2.6cm nodule in the left lower lobe with a 4mm satellite nodule. CT guided biopsy and PET scanning confirmed T2a N1 M0 adenocarcinoma of the lung. Curative surgical resection is planned.
Results: Hypertrophic osteoarthopathy presents with clubbing, bone periositis, joint pain and swelling. Causes include primary lung cancer, mesothelioma, thymoma, chronic respiratory infections such as pulmonary abscess, pulmonary fibrosis and rarely; GI tract pathology. Hypertrophic pulmonary osteoarthopathy (HPOA) is a rare presenting feature of lung cancer, with confirmed HPOA accounting for around 0.8% of patients in a recent study of 1200 patients with lung cancer. It is reported that lung cancers can only be seen on chest X-rays when the tumour is at least 6-8 mm or larger. In a recent study of 260 patients nearly 25% had received a chest X-ray reported as normal within 1 year of a subsequent diagnosis of lung cancer. Our patient's tumour was obscured by the diaphragm and was not visible on the PA chest X-ray. The CT allowed detection of the tumour early enough for curative treatment. Conclusion: It is our opinion that Rheumatologists should consider CT scan of chest and not just a chest X-ray in all new presentations of unexplained hypertrophic pulmonary osteoarthopathy. Disclosure statement: The authors have declared no conflicts of interest. Background: Occipital horn syndrome (OHS) is a very rare, X-linked genetic disorder. There are 20 cases reported. It is a disorder of copper metabolism caused by missense mutations in the ATP7A gene, leading to toxic cellular accumulation of copper. This is the less severe phenotype of the condition known as the childhood variant of Menkes disease. We present a case report of a male with this syndrome who evaded clinical diagnosis for many years, with interesting radiological findings of rib notching which has not been associated with this condition. Methods: A 25 year old male presented with a diaphyseal skeletal dysplasia with abnormal carpal bones, radial shortening, humeral abnormalities, abnormal femoral head development and exostoses. Of note were inferior and superior rib notching. As a child, he was noted to have hypotonia, skin laxity, hyper-extensible joints and delayed developmental milestones. During his teenage years, he suffered from short stature and delayed puberty. He had experienced considerable myalgia and polyarthralgia with associated weakness compounded by pain and fatigue. He required multiple surgical interventions for paraumbilical, femoral and inguinal hernias since infancy. He was treated for multiple bladder infections secondary to diverticula; leading to numerous surgeries, including a left sided nephrectomy for nonfunctioning kidney. He was diagnosed with mitral valve prolapse as a child. Recently, he has suffered from short lived irregular palpitations with dyspnoea, triggered by posture changes. He had prolonged QTc interval on electrocardiogram but cardiac MRI was unremarkable. On examination, he demonstrated a long neck and forehead with narrow face, elevated arched palate and micrognathia. There was evidence of lax skin, reduced subcutaneous fat and markedly hypermobile joints. There was marked exostosis at the elbows with fused radial heads. He had narrow shoulders with expanded clavicular-sternal joints, as well as pectus excavatum. Results: On specialist review of the patient's skeletal imaging, large exostoses (calcifications) were found in his trapezius and sternocleidomastoid muscles. These are the characteristic occipital horns, which married together with the spectrum of the connective tissue phenotype led to confirmatory blood and genetic testing showing low plasma copper and caeruloplasmin as well as the pathogenic mutation. Subcutaneous copper histidine replacement injections have been tried in Menkes disease and it is thought to slow disease progression. The use of copper in OHS is less certain. Conclusion: Occipital horn syndrome is worth considering as a diagnosis in cases with specific connective tissue phenotypes and odd radiological features. Inferior and superior rib notching has a short differential list and OHS should be added to this. This case illustrates the need for multiprofessional specialist services including the clinical genetics department. Diagnosis is important to establish in terms of monitoring organ complications and to plan antenatal screening and treatments that may improve long-term outcome. We report a patient with chronic lymphocytic leukaemia (CLL) that was treated with Idelalisib, a PI3K inhibitor and rituximab who developed classical signs and symptoms of polymyalgia rheumatica (PMR). The occurrence of PMR in cases of immune potentiation is a more common than PMR occurring in patients on immunosuppresive therapy. Methods: An 85 year old lady with CLL, initially conservatively managed for two years presented with a three month history of increasing pain around her neck, shoulders and thighs, early morning stiffness lasting more than one hour and difficulty getting out of the bed. Twenty weeks into the trial, with Rituximab 375mg administered intravenously once weekly for 8 weeks and Idelalisib 150mg tablets twice daily she had reduced power in all four limbs with some reduction in the range of active movement. There was no neurological impairment, obvious synovitis or myositis. Her CRP was 74 mg/l and she had a negative autoimmune screen with ANA, ANCA, RF, ACPA and normal serum complement levels and creatine kinase. She was commenced on 15mg of prednisolone. Three weeks later she was taking 12.5mg of prednisolone and had complete resolution of her symptoms with a CRP of 5.7 mg/l. At 9mg of prednisolone her symptoms returned and her CRP rose to 39 mg/l. She was then advised to take 10mg and taper her steroids slowly. Throughout she continued to take Idelalisib and from a CLL perspective she responded extremely well. Results: Although immunologically mediated events are well recognised with Idelalisib, especially enterocolitis, hepatotoxicity, diarrhoea, pneumonitis, this is the first report of Idelalisib being linked to PMR. Given the long history of rituximab use and its non-association with PMR development, it is likely that Idelalisib is responsible, but of course there could be an interaction between the two and PMR development. As Idelalisib has now been approved by NICE for CLL, and is being widely used, clinicians need to be aware of these adverse effects. The association between PMR in patients on Immunosuppressive therapy has, to our knowledge, been reported once in a renal transplant patient on triple therapy (tacrolimus, mycophenolate mofetil, and prednisone). It was a classic presentation with raised inflammatory indices. This patient had complete remission of her symptoms following an increase in her prednisolone dose. Reports of drug-associated PMR/GCA have been documented as occurring in two patients after treatment with Ipilimumab, an antagonist of CTLA-4. Conclusion: In patients presenting with classical signs and symptoms of PMR, a thorough history, physical examination and monitoring of inflammatory markers must be undertaken. Interestingly this case clearly highlights the need to be vigilant in considering cases of PMR in patients on immunosuppressive therapy. Although it is unusual, this phenomenon can occur. We have previously investigated the interplay between TGF-b, BMPRII, VEGF and endothelin in SSc using the TbRIIDk-fib strain, a transgenic mouse model of balanced upregulation of TGF-b signalling. The pivotal role of endothelin within this multifaceted pathology was confirmed using macitentan, a licensed endothelin receptor antagonist of proven efficacy, to prevent and treat pulmonary hypertension in this model. We have extended these studies to examine whether cellular pathways targeted by modern therapies currently undergoing clinical trials in SSc are altered in this model of constitutive skin fibrosis and pulmonary vasculopathy. Methods: RNA was isolated from cultured skin and lung fibroblasts and aortic smooth muscle cells (SMCs) explanted from transgenic and wildtype littermate control mice and subjected to gene expression analysis using the Illumina microarray platform (n ¼ 3 each group). Inflammatory, vascular and fibrotic cellular pathway components targeted by therapeutic agents undergoing multicentre clinical trial evaluation in SSc were identified and gene arrays were analysed looking for relevant differentially-expressed genes, defined as at least a 2-fold average change from wildtype comparator samples with p < 0.05. Results: There were between 50 and 400 differentially expressed genes from the cell lines examined. These gene lists were then examined to identify genes involved in the nitric oxide synthase pathway and downstream mediators (riociguat); IL-6 receptor and downstream pathways (tocilizumab) and PDGFR, FGFR and VEGFR axes (nintedanib). In particular, several genes involved in nitric oxide metabolism were altered in lung fibroblasts, including NOS2, PTGIS and GUCY1A3. Genes also involved in vasoconstriction were differentially expressed in aortic SMCs, including upregulation of multiple phosphodiesterases and the vasoconstrictor PTGS-1 (COX-1). IL-6 gene expression was upregulated in transgenic skin and lung fibroblasts, as was STAT1, STAT3 (fold change 36:1, p < 0.004 in skin fibroblasts) and JAK1 expression. In contrast, gp130, STAT3 and PIAS3 were all downregulated in SMCs. Pathways related to the mechanism of action of nintedanib are more complex since several of these downstream mediators form the non-canonical signalling pathways of TGF-b and are known to be altered in this mouse model. As expected we identified multiple genes involved in these axes, for instance, upregulation of PDGFRA (fold change 137:1, p < 0.02), FGF10, FGFR1 and downregulation of Ras and related proteins in SMCs. 
COMPELLING CASE OF COPPER CONUNDRUM: OCCIPITAL HORN SYNDROME
METHYL CAP BINDING PROTEIN 2 IN SYSTEMIC SCLEROSIS
Steven O'Reilly Health and Life Sciences, Northumbria University, Newcastle Upon Tyne, UNITED KINGDOM Background: Systemic sclerosis (SSc) is an autoimmune idiopathic rheumatic disease that is characterized by skin fibrosis and activation of fibroblasts to myofibroblasts. This conversion of fibroblasts to myofibroblasts results in copious amounts of ECM release and this leads to scarring. The transition is under epigenetic control and likely involves DNA methylation of the fifth carbon of cytosine. This leaves the epigenetic methyl mark that is repressive. Methyl Cap Binding Protein 2 (MeCP2) is a protein that binds to the methylated DNA helping the DNA repression of the particular gene in a large protein complex and is mutated in Rett syndrome an autistic spectrum disorder. We have previously seen upregulation of MeCP2 in dermal fibroblasts from SSc patients and that this is induced by TGF-b1. The aim of the present study was to examine the mechanism of how MeCP2 is involved in fibrosis. Methods: MeCP2-GFP plasmids under a strong promoter were generated. Primary healthy dermal fibroblasts were transfected with MeCP2-GFP-pDest vectors or empty GFP-only plasmids with Viromer Yellow transfection reagent and after 48 hours the cells were harvested and analysed for ECM by western blotting. Using the bleomycin mouse model of SSc in which bleomycin induces a fibrotic skin phenotype the skin tissue of the mice was analysed for MeCP2, collagen and Axin2 by qPCR and normalized to a housekeeping gene (18S) for relative differences between treated and vehicle treated mice. Results: Forced overexpression of MeCP2 could be confirmed to be efficient by GFP analysis by confocal microscopy in the dermal fibroblasts. Overexpression of MeCP2-GFP led to enhanced expression of collagen 1 at the protein level compared to GFP-pDEST vector transfection alone. The MeCP2-induced collagen expression could be abrogated by Wnt inhibitor incubation, suggesting Wnt is a mediator. Using the bleomycin model of fibrosis in which the skin is fibrotic we found elevated MeCP2 and collagen mRNA expression. Also using the Wnt target gene Axin2 as a target gene of Wnt activation we demonstrated a highly significant increase in Axin2 levels by qPCR compared to vehicle treated mice. Treatment of fibroblasts with Wnt3a leads to increased collagen levels. Conclusion: Epigenetic modification by enhanced MeCP2 levels appears critical in myofibroblast transformation. The enforced overexpression of MecP2 leading to increased levels of collagen appears dependant on the Wnt pathway. The Wnt target gene Axin2 is elevated in the bleomycin mouse model of fibrosis coincident with the expression of the epigenetic modifier MeCP2 and collagen gene, suggesting the two proteins are linked. Wnt3a treatment of fibroblasts induces collagen expression. There is an epigenetic loop involving MeCP2, DNA methylation and aberrant Wnt signalling in systemic sclerosis. Disclosure statement: The author has declared no conflicts of interest. Background: Calcinosis cutis (sub-or intracutaneous deposition of calcium salts) is a major clinical problem associated with systemic sclerosis (SSc) as well as other rheumatological disorders. Calcinotic lumps, usually deposited around pressure points such as fingers, knees or elbows, trigger pain and frequently lead to manual disability, as well as skin infection and ulceration. Pathogenesis of calcinosis remains unknown, even though some links to ischemia, vascular calcification and trauma have been reported previously. This research aimed to establish the protein composition of SSc-related calcinotic deposits and assess whether this might offer useful insights into pathogenesis. Methods: Four solid and one liquid calcinotic deposits were collected from five patients with SSc. 5 mg of the deposits were boiled in SDS buffer for 7 mins and electrophoresed for 5 mins in polyacrylamide gel. Next, protein bands were excised from gel, dehydrated with acetonitrile and vacuum centrifugation, reduced with 10mM dithiothreitol, alkylated with 55mM iodoacetamide, washed twice with 25mM ammonium bicarbonate and acetonitrile, dried by vacuum centrifugation and digested with trypsin overnight. Digested samples were analysed using UltiMate 3000 Rapid Separation LC (Dionex) coupled to an Orbitrap Elite (Thermo Fisher) mass spectrometer. Data produced were searched using Mascot (Matrix Science UK) against the Swissprot and Uniprot databases with human taxonomy selected. Data were validated using Scaffold (Proteome Software). Results: 424 and 489 proteins in total were identified in calcinotic deposits when screened against Uniprot and Swissprot databases, respectively. However, all samples had 77 proteins in common and these were the subject of quantitative analysis. Human serum albumin (HSA) was consistently the single most abundant protein in all samples, accounting on average for 14% of the total protein content [>300 normalized unique peptide sequences (NUPS) per deposit]. Interestingly, the one liquid calcinosis sample had twice as much HSA as the solid samples (1112 as opposed to 416 NUPS, respectively). Further analysis indicated that almost 50% of proteins in calcinotic deposits were likely to have originated from components of immune system (neutrophils, 27%; immunoglobulins, 13%; complement system, 7%). Negligible amounts of protein from microorganisms were found in only two out of five calcinotic deposits, implying that the presence of immune system components is related to pathogenesis rather than infection. Conclusion: Our research implicates HSA as a primary biological player associated with the formation of calcinotic deposits. The high levels of immune proteins present suggest that these sites promote significant inflammatory response. Disclosure statement: The authors have declared no conflicts of interest. (PsA) is an inflammatory arthritis associated with psoriasis affecting the joints and connective tissue. Clinical features include: enthesitis, dactylitis, spondylitis and inflammation. According to the common-sense model (CSM), patients develop illness beliefs when faced with new symptoms, which determine their emotional and behavioural response to the condition. The CSM includes five beliefs: identify, causes, consequences, time line and control/cure. These are important determinants of outcome and have been shown to influence adherence to medication. Methods: A secondary analysis of data from eight focus groups carried out at five hospital sites was conducted. Focus groups were audio-recorded, transcribed and anonymized as part of the PROMPT study. Data were analysed by the lead researcher (G.E.) and two team members (S.H. and E.D.) using deductive thematic analysis, based on the illness perceptions framework. Results: Forty-one patients sampled for a range of phenotypes and domains of disease activity participated: men¼20 and women¼21; mean age¼58 years (SD 11.4); mean disease duration¼9 years (SD 8.3); mean HAQ¼1 (SD 0.7). There was evidence to support the existence of the five illness beliefs among patients with PsA and evidence that these beliefs may affect the way patients engage with their condition. However, there were also data that did not fit the model, suggesting that external factors also influence patients' beliefs. Six themes were thus developed with an overarching theme of uncertainty. Identity: there was uncertainty surrounding the diagnosis of the condition-''Á Á ÁI'm not sure the label's right''. Plus evidence to suggest that the uncertainty stemmed from a lack of communication-''no-one's actually telling me what the problem is''. Causal: uncertainty around the cause of the condition and the presenting symptoms was evident -''Is it the psoriatic arthritis or is it the fibromyalgia''? Plus further evidence for a lack of communication-''Nobody has ever explained that fatigue . . . goes along with this disease''. Time line: uncertainty and anxiety around the prognosis of the condition-''How am I going to end up''? Consequence: uncertainty around the long-term side effects of medication-''that anxiety of not knowing what's going to happen''. Control: data suggested a focus on physical symptoms and a lack of psychological support-''you need help and support''. External: emerging from the data was the impact of external factors, e.g. peoples' perceptions of the condition-''If somebody was to see us now they'd say what's wrong with these guys''? Conclusion: Overall there was uncertainty around the condition and medication, potentially stemming from a lack of communication from health care professionals. The uncertainty focused on the prognosis and symptoms of PsA, causing anxiety and distress. It could be that this uncertainty influenced participants' behaviour towards medication. Disclosure statement: The authors have declared no conflicts of interest.
PROTEIN COMPOSITION OF SYSTEMIC SCLEROSIS-RELATED CALCINOTIC DEPOSITS
THE ILLNESS PERCEPTIONS OF PEOPLE WITH PSORIATIC ARTHRITIS: A SECONDARY ANALYSIS OF FOCUS
HYDROXYCHLOROQUINE-INDUCED RETINAL TOXICITY
Andrew B. Allard, Elizabeth Bristow, Gill Coombes, Sarah Hickey, Hilary Johnson, Ramesh Mootoo and Elaine Smith Rheumatology, Gloucestershire Royal Hospital NHS Trust, Gloucester, UNITED KINGDOM Background: Hydroxychloroquine (HCQ) is a well-tolerated medication with few significant side effects compared to other diseasemodifying anti-rheumatic drugs. Retinal toxicity is one serious, irreversible complication and published data have shown that this risk is dependent on daily dose and duration of use. At recommended doses, the risk of toxicity with 5 years treatment is < 1% and up to 10 years is < 2%, but after 20 years it increases to almost 20%. The recently revised American Academy of Ophthalmology recommendations on screening suggest a maximum daily dose of 5.0 mg/kg actual body weight. We report 2 cases of HCQ-induced retinal toxicity in patients seen at Gloucestershire Hospitals NHS Foundation Trust in the last year. The first presented with deteriorating visual acuity. The second was asymptomatic but was diagnosed following referral for ophthalmology assessment after a high cumulative HCQ dose was identified. Both were found to have classical findings for severe HCQinduced retinal toxicity, including bullseye appearance on retinal photography and fluoroscopy with parafoveal scotomas on 10-2 automated visual field testing. Methods: As a result of these cases we undertook an audit to evaluate the numbers of patients in our centre on HCQ and their respective cumulative doses. All rheumatology consultant-based clinic encounters over a 3 month period were reviewed retrospectively. Patients currently taking HCQ were identified and their records reviewed. Data were collected on demographic characteristics, HCQ dose in mg/kg actual body weight and cumulative dose. Results: There were 226 consultant-led rheumatology clinics in the preceding 3 month period. 1808 clinical encounters were reviewed and 177 patients currently taking HCQ were identified. Average age was 59.3 years and the female:male ratio 4.5:1. 22 patients were excluded as they were no longer taking HCQ or there were insufficient data available. Of the remaining 155, 22 patients had received >1000g (2 had received >2000g); 7 had received 900-1000g; 31 are currently receiving >5mg/kg/day actual body weight. 52 patients were commenced on HCQ >5 years ago. Conclusion: Current guidelines for eye monitoring of HCQ in the UK recommend local arrangements for those taking the medication for >5 years. Our findings support recent evidence that the risk of retinal toxicity is higher than was previously thought. We suggest patients who have received >1000g cumulative dose should be considered for formal assessment by an ophthalmologist for appropriate retinal imaging. This might include a combination of retinal photography, video fluoroscopy, 10-2 Visual Fields, optical coherence tomography or multifocal electroretinography. Further work is needed to develop specific guidance on how to implement these investigations as part of an effective screening strategy. In addition, all patients on HCQ should have an up-to-date weight recorded at clinic appointments and their dose adjusted if they are receiving >5mg/kg actual body weight. Disclosure statement: The authors have declared no conflicts of interest.
AN UNUSUAL CASE OF RASH AND JOINT PAIN
Megan MacDiarmid and Carolyn Bell
Rheumatology, Worcestershire Royal Hospital, Worcester, UNITED KINGDOM Background: A 43 year old Caucasian male presented to the Dermatology clinic with a one year history of a pruritic eruption over his arms, neck and chest. Topical steroids and anti-histamines offered limited relief. He also described joint pain and stiffness affecting his hands and knees over the same period. A rheumatology consult uncovered symptoms of polyarticular symmetrical small joint and knee arthralgia in the absence of typical features of inflammation such as swelling, stiffness or diurnal variation. He also described drenching night sweats. A course of Naproxen and Prednisolone substantially improved his joint symptoms. He was an ex-smoker with no other significant co-morbidity, occupational exposure or family history. Methods: Examination revealed multiple, discreet, shiny, firm papules and small nodules over the cheeks, neck, above the eyebrows and at periungual sites. Erythema around the neck, multiple xanthelasma and a warm moderate left knee effusion were present. Systemic examination was otherwise normal. The initial differential diagnosis included amyloidosis, sarcoidosis, dermatomyositis and cutaneous mucinosis. Further confirmatory tests were sought: ACE was mildly elevated (80 ml) otherwise blood testing was unremarkable including: FBC, creatinine, LFTs, CRP, ESR, CK, hepatitis screen, HIV, ANCA, ANA, dsDNA, ENA, complements, CCP, RF and urate. Total cholesterol was 5.4 and triglycerides 1.9. Plain X-rays of the hands and knees were normal. CT of the thorax, abdomen and pelvis showed no evidence of malignancy. A 6mm punch biopsy from the posterior neck showed an epidermal collarette enclosing a circumscribed cluster of mononuclear and multinucleate histiocytes with eosinophilic ground glass cytoplasm. This is diagnostic of Multicentric Reticulohistiocytosis (MRH). Results: Reducing oral steroids with combination therapy of hydroxychloroquine 200mg daily and Methotrexate 15mg weekly were commenced to good effect. Erythema, arthralgia and systemic upset settled with flattening of the nodules and papules. His symptoms flared once the course of oral steroid was complete, requiring titration of the methotrexate dose to 20mg weekly. He remained stable on this regimen until he contracted Zika virus, necessitating temporary withdrawal of DMARDs. Conclusion: MRH is a rare systemic disorder characterized by papulonodular skin lesions in a coral bead pattern. Half of those affected develop a severe, destructive polyarthritis. In rare cases, there may be systemic involvement including of the respiratory tract, liver and spleen. The aetiology is unknown. Around 25% of cases are associated with malignancy and patients should be screened at diagnosis. Treatment is usually with steroids and methotrexate but cyclophosphamide may be required to control the destructive arthritis. There are case reports of anti-TNF therapy being used to good effect. MRH is a rare but important differential of rash and joint pain. Prompt and aggressive treatment is required to prevent destructive arthritis. Affected individuals should be monitored for evidence of systemic involvement and malignant disease. Disclosure statement: The authors have declared no conflicts of interest. Background: Behç ets disease (BD) is an idiopathic, multi-system disorder of a vasculitic nature, characterized by mouth and genital ulcers, rash, arthritis and uveitis. Ocular manifestations occur in up to 80% of patients with BD with 30% risk of blindness. We present a challenging paediatric case of BD-associated bilateral pan-uveitis and aggressive refractory uveitis affecting the left eye. Methods: An 11 year-old girl presented acutely with a three-day history of a painful red left eye and blurred vision. Examination revealed bilateral uveitis with optic disc swelling, cystic macular oedema (worse in left eye), 2þ and 3þ cells in her right and left eyes respectively (Standardization of Uveitis Nomenclature classification) with snowballs and reduced visual acuity. A two-year history of mouth and genital ulcers was given and at presentation mild peripheral-joint arthritis was detected. Initial treatment with intravenous methylprednisolone, intensive steroid eye drops and subcutaneously administered methotrexate (15mg/m 2 ) was commenced. Infliximab (6 mg/kg intravenously 4-weekly) and mycophenolate mofetil (600mg/m 2 orally twice-daily) were subsequently added for multi-focal chorioretinitis in the left temporal retina. Infliximab was changed to tocilizumab (8mg/kg intravenously 2-weekly) in response to uveitis flares and reduced vision as a result of persisting chronic cystoid macular oedema. Subsequently tocilizumab was changed to adalimumab (40mg subcutaneously fortnightly), however a pattern of repeated sight-threatening uveitis flare-ups and persisting cystic macular oedema. Fifteen months after initial presentation mycophenolate mofetil and adalimumab were substituted for pulsed intravenous cyclophosphamide (initially 500mg/m 2 fortnightly, increasing to 1g/m 2 3-weekly; total 6 doses) for pseudo-hypopyon, recurrent widespread multi-focal chorioretinitis and acute sight loss (6/60). Multiple pulses of intravenous methylprednisolone and oral prednisolone were given throughout the treatment course in response to repeated flare-ups of inflammation associated with reduced visual acuity due to macular oedema. Despite cyclophosphamide treatment further severe flare-ups of eye disease complicated by pseudo-hypopyon, optic-disc swelling, multi-focal choroiditis and pseudo-necrotizing retinitis occurred. Following cyclophosphamide, interferon-alfa-2A (3 million units subcutaneously daily) was commenced resulting in sustained and complete remission of eye inflammatory features including previously refractory cystic macular oedema; vision improved significantly to 6/9þ. To date interferon-alfa has been well tolerated and demonstrated clinical effectiveness from the first week. Throughout the treatment pathway we collaborated with colleagues in national centres of expertise for paediatric BD and uveitis. Results: Interferon-alfa has controlled intraocular inflammation, led to reduced macular oedema and improved vision; to date the patient remains in remission from uveitis. In this case interferon-alfa has been well tolerated but other BD manifestations (mouth and genital ulcers and arthralgia) have worsened.
INTERFERON-ALFA USED TO TREAT A CHALLENGING CASE OF REFRACTORY PAEDIATRIC BEHÇ ETS DISEASE WITH SIGHT-THREATENING UVEITIS
Conclusion: Interferon-alfa was successful in treating this child's panuveitis and cystoid macular oedema, which previously had proved refractory to multiple immunosuppression agents. To the best of the authors' knowledge, this is the first UK case of paediatric BD-uveitis treated with interferon-alfa. Background: Leprosy is an infectious disease caused by Mycobacterium leprae that involves the skin and peripheral nerves. It is an important health concern in certain areas. Early diagnosis and treatment are critical for preventing lifelong disability. Inflammatory polyarthritis is an unusual presenting symptom. Nasal discharge from untreated patients frequently contains large numbers of bacilli with high risk of transmitting the disease. Methods: We report the case of a Nepali lady, who presented with rheumatoid arthritis like picture. Results: Our patient is a 32 years old married Nepali lady, who works in a kindergarten and who was previously healthy. She presented with joint pain and swelling involving hands, wrists, feet and knees of two weeks duration with early morning stiffness. She reported no constitutional symptoms or anything to suggest connective tissue disease. She came from Nepal nine months ago. She looks well. She had pitting edema of hands and feet with a pit dark skin with inability to make a full fist. There is tenderness and swelling of wrists, MCP joints, PIP joints, MTP joints, ankles and knees. We also noticed faint erythematous, non-blenching, non-itchy macular lesions which involves face, neck and chest with no sensory loss over the lesions. There is no lymphadenopathy. Investigations: hemoglobin 8.5 mg/dl with normal WBC and platelets. Inflammatory markers raised with ESR 66, CRP 208 mg/L. U&Es, LFTs, Urine dipstick, hand X-rays were all normal. Virology screen: Parvovirus-B19 IgG Positive (IgM negative). ACCP, RF, ANA and ENA were Negative. Patient was initially treated as case of possible viral arthritis with naproxen, but with no response. Another possible diagnosis thought to be early RA, but as the history was short; we refrained from starting her on DMARDs. We also did not give her steroid as she is from Nepal and our policy is to exclude infection in such cases. We did a skin biopsy for her unexplained rash. Later on the histopathology confirmed leprosy. It showed several foci of superficial and deep epithelioid granulomata with focal extension into the subcutaneous fat and around nerves. Wade-Fite, ZN and silver stain revealed a large number of bacilli with a more diffuse histiocytic infiltrate consistent with leprosy. Immunofluorescence studies were negative. Patient was sent to the infectious disease clinic for leprosy treatment. Conclusion: Leprosy is very unusual cause of arthritis mimicking RA. High index of suspicion to exclude unusual infection including Leprosy is essential for patients coming from areas endemic with such diseases. Clinicians should look carefully for clues such as skin rash that may lead to the correct diagnosis. Disclosure statement: The authors have declared no conflicts of interest. Background: Certolizumab pegol is an anti-tumour necrosis factor (anti-TNF) inhibitor that is used for severe forms of rheumatoid arthritis. The prevalence of heart failure in the general population is more than 23 million worldwide. Cardiovascular disease has an increased prevalence of 35-50% in the RA population and this is likely to be multifactorial. The reported incidence of heart failure (the Framingham criteria) is 2 in 1000 people. Rheumatoid arthritis is said to double the risk of heart failure in comparison to healthy population that is not explained by cardiovascular risk factors. Anti-TNF inhibitors are contraindicated in patients with NYHA class III/IV heart failure. However, there is little knowledge about biologic-induced heart failure in RA. Methods: We report a patient with severe RA that developed significant left ventricular heart failure following commencement of certolizumab pegol. Results: A 41 year old male baker with no past medical history presented to a rheumatology clinic with a four month history of progressive joint pain and swelling associated with several hours of morning stiffness. On clinical examination he had twenty-seven swollen joints and nine tender joints. Cardiovascular examination was normal. Initial blood screening showed normocytic anaemia, a high platelet count of 516 Â 10 9 /l. The CRP was 303 mg/L. The patient was diagnosed with aggressive seronegative rheumatoid arthritis and started on oral prednisolone (20mg daily), hydroxychloroquine and oral methotrexate with rapid escalation to 25mg weekly. He was not taking regular non-steroidal anti-inflammatory drugs. Despite these measures his disease remained active three months later (DAS28-CRP of 7.63). Certolizumab pegol was added to his treatment. Biologic treatment necessitated isoniazid for possible latent tuberculosis. His DAS28-CRP score improved to 4.85. After three months If biologic treatment and following completion of isoniazid, he presented with a week long history of productive cough and breathlessness. He was treated for a lower respiratory tract infection and advised to stop Certolizumab pegol. Clinical examination was in keeping with heart failure. Troponin I tests were negative on two occasions. His CRP was 63 mg/L. Echocardiograph showed a moderately dilated left ventricle with mild symmetrical hypertrophy and severely reduced systolic function. Cardiovascular risk factors included tobacco smoking (5 cigarettes per day) and his mother had a stroke at age 40. After stopping Certolizumab pegol and initiation of heart failure medications he had symptomatic improvement and was able to return to his employment. Subsequent cardiac MRI showed mild dilated cardiomyopathy with a return of normal cardiac function. Conclusion: Heart failure is a recognized but rare complication of biologic therapy. We present the first published case of Certolizumab pegol-induced heart failure in a low risk patient with clear resolution of symptoms with discontinuation of Certolizumab pegol. Disclosure statement: The authors have declared no conflicts of interest.
CERTOLIZUMAB-INDUCED HEART FAILURE
MONOARTICULAR JOINT PAIN AS A FIRST PRESENTATION OF A METASTATIC SQUAMOUS CELL CANCER
Karina Lazarewicz, Frank McKenna and Preeti Shah Rheumatology, Trafford General Hospital, Manchester, UNITED KINGDOM Background: Metastatic synovial deposits are a rare finding in medical practice. We report a patient who presented with a monoarthritis of the elbow from a metastasis. Methods: A 50 year old male shredding company manager presented to the rheumatology clinic with a 4 week history of painful left elbow. He associated the start of the symptoms with a low impact trauma he sustained at his office. He has past medical history of tonsillar squamous cell carcinoma (T1 pN2b) that was treated with local excision, radiotherapy and chemotherapy in July 2015. He was a lifelong non-smoker. There was no history of psoriasis or inflammatory eye or gut disease. Over the previous 6 weeks he reported unintentional weight loss and a persistent cough. The chest X-ray showed right upper zone lung shadowing that was not responding to antibiotics from his GP. On clinical examination he was apyrexial. He had a fixed flexion deformity of the right elbow with tenderness and diffuse swelling of the joint. There was no synovitis in any of his other joints. His inflammatory markers were mildly elevated (CRP 31 mg/L, ESR 44 mm/hr) and the rheumatoid factor was negative. An X-ray of his elbow was reported as normal. He was admitted to hospital and his elbow aspirated. The joint aspirate was turbid and showed leucocytes but no bacterial growth. An MRI of his left elbow revealed a metastatic joint deposit. A CT of the thorax showed a right upper lobe mass consistent with a lung cancer. Cytology of the synovial fluid found squamous cell carcinoma. A fine needle biopsy of a supraclavicular lymph node confirmed metastatic squamous cell carcinoma. Results: Adenocarcinoma is the most common cancer that has been associated with synovial metastases followed by squamous cell carcinoma. There are about 50 case reports of metastatic synovial deposits, but the most common presentation is metastatic synovial deposit in the knee joint secondary to adenocarcinoma of the lung. Joint metastases carry a poor prognosis with a mean survival of about 5 months.
Conclusion: This is, to our knowledge, the first reported case of a metastatic squamous cell carcinoma in an elbow joint. Synovial joint metastases are extremely rare and they carry a poor prognosis. This case emphasizes the importance of taking a full history and to consider malignancy when assessing a patient with monoarticular pain. Disclosure statement: The authors have declared no conflicts of interest.
A RARE CASE OF PRIMARY BILATERAL OBTURATOR MUSCLES PYOMYOSITIS LIKELY RELATED TO SHAVING
Liubov Borukhson, Priyanka Agrawal and Krishna Baburaj Rheumatology, Watford General Hospital, London, UNITED KINGDOM Background: Pyomyositis is an acute, potentially life-threatening bacterial infection of the skeletal muscles. It is very unusual to develop pyomyositis in an immunocompetent patient. Our patient developed pyomyositis most likely as a result of shaving his thighs in the week preceding his symtoms. Also, the most commonly affected muscle groups are the quadriceps, gluteal and iliopsoas. Our patient developed pyomyositis in the obturator muscles, and it was bilateral, which is rare. Methods: A 47 year old gentleman was admitted with a three day history of fever, rigors, feeling unwell. He had a progressively worsening bilateral proximal lower limb weakness and was unable to walk. He had no significant past medical history. The patient denied any history of recent travel, trauma, viral illness, extreme exercises or IV drug use. On examination he was pyrexial at 38.18C. He had reduced power in the proximal muscles of both lower limbs with normal reflexes and sensation. He also had tenderness over the anteromedial aspect of both thighs and in the suprapubic area. Results: Blood tests on admission revealed an elevated CRP of 328 mg/l, WCC of 9.4 Â 10 9 /l and CK of 340 IU/l. The septic screen was unremarkable as well as CT scan of the abdomen and pelvis. Serology for HIV, Hepatitis B and C was negative. A screen for autoimmune disease (including ANA, RF), as well as immunoglobulins, was negative. Blood cultures were positive for Staphylococcus aureus sensitive to flucloxacillin. X-rays of the legs showed no osteomyelitis. CT of the abdomen and pelvis showed no intra-abdominal fluid collection or psoas abscess. MRI of the pelvis revealed multifocal pyomyositis with collections in the left obturator externus and right obturator internus muscles. He was diagnosed with primary multifocal pyomyositis occurring in an immunocompetent host. On detailed history taking, the patient reported shaving of his thighs bilaterally a few days prior to the onset of symptoms. The patient was initially treated with empirical intravenous tazocin, while awaiting blood culture sensitivities. His leg pain worsened, with radiation across the groin. He was switched to intravenous flucloxacillin and rifampicin. Due to the size and multifocal nature of the bilateral obturator collections, they were not amenable to drainage by the orthopaedic surgeon or interventional radiologist. Our patient's repeat MRI of the pelvis after completing three weeks of intravenous antibiotics showed complete resolution of the right obturator collection and near complete resolution of the left obturator collection, with some residual oedema. His blood tests normalized and he was walking unaided. Conclusion: We encourage clinicians to maintain an index of suspicion for pyomyositis in patients with myalgia and fever in the absence of significantly elevated muscle enzymes. Our case had a favourable outcome in spite of extensive muscle involvement. Disclosure statement: The authors have declared no conflicts of interest.
PARANEOPLASTIC VASCULITIS IN OCCULT LUNG MALIGNANCY
Zeeshan Khan and Srishti Gupta Rheumatology, Hull Royal Infirmiry, Hull, UNITED KINGDOM Background: Paraneoplastic syndromes are localized or diffuse pathologic manifestations that may occur in subjects affected by neoplastic diseases. Among the multiple clinical manifestations of paraneoplastic syndromes, cutaneous presentations are quite common. It is estimated that in about 1% of cases, skin manifestations may represent the first diagnostic sign of a neoplastic disease. We report a case of paraneoplastic vasculitis in a patient with occult lung malignancy. Methods: A 78 year old lady, presented with six week history of pain and discolouration of a right middle finger. She was known to have rheumatoid arthritis but otherwise well. On examination, right middle finger pulp appeared necrotic at the tip and was tender to palpation.
She had facial telangiectasia and splinter haemorrhages in both hands. The distal pulses in all the limbs were present, however, peripheries were cold. She was tachycardic with a pulse of 109 bpm but the remaining observations were normal. There were no eye signs, rash or joint pain. Her systemic examinations were unremarkable. The initial laboratory results were: Hb 91 g/L, WCC 27.3 Â 10 9 /L, Platelets 437 Â 10 9 /L, GFR >90 ml/min, CRP 172 mg/L, CK 25 with normal liver function. ECG showed sinus tachycardia, chest X-ray showed an illdefined small opacity in the right middle zone and urine dipstick showed haematuria. The initial clinical impression was infective endocarditis, however, vasculitis was also a differential. The transthoracic echocardiogram did not show any vegetations and three sets of blood cultures were negative. The immunology and vasculitic screen were normal. Results: She was started on dual anti-platelet therapy and iloprost infusion for the ischeamic finger. She was also started on prednisolone 40mg once a day for the likely autoimmune vasculitis. Later, she developed pain in the left foot. On examination, she had paraesthesia in her toes and lateral aspect of the sole along with calf tenderness. Ultrasound Doppler did not show any evidence of venous thrombosis. The pain and numbness progressed to both lower limbs. Her finger discolouration and pain started to improve with three iloprost infusions. Computed Tomography of the thorax showed a lesion in the right upper lobe suspicious for malignancy with no distant metastasis. She underwent percutaneous biopsy of the lung lesion which confirmed Adenocarcinoma. A diagnosis of vasculitis secondary to paraneoplastic syndrome was made and the patient was planned to have a right lobectomy. Conclusion: Case series have shown resolution of vasculitis following the effective treatment of malignancy. Any recurrence of vasculitis is a marker of tumour recurrence or progression, thus providing strong evidence for vasculitis being a true paraneoplastic syndrome. Vasculitis with poor response to usual therapy, especially in elderly patients, should raise a question about underlying malignancy. Disclosure statement: The authors have declared no conflicts of interest. Background: Methotrexate is widely used in the treatment of inflammatory arthritis and vasculitis. Paradoxically vasculitis is rarely an adverse reaction to methotrexate, with scant literature in the context of juvenile rheumatic disorders. Methods: We report a case of Methotrexate-induced medium vessel vasculitis in a child with systemic onset juvenile idiopathic arthritis (SoJIA). Results: A 10 year-old previously healthy boy presented with headache, abdominal pain, neck stiffness, quotidian fevers, polyarthritis and evanescent, salmon-pink, fever-associated rash. Investigations for malignancy, autoimmune disease, infections were negative. He had microcytic anaemia (Hb 7.9 g/dL, WC 8.0, Pl 164) and persistent high CRP (215-419). SoJIA was diagnosed and he responded to nonsteroidal anti-inflammatory drugs and oral prednisolone (20-30mg/day). Over the subsequent 6 months he had two flares of SoJIA. He was commenced on Methotrexate 10mg subcutaneously. The day after the first dose an erythematous, raised coin-shaped rash appeared on the medial border of his right foot. Over the subsequent 5 months he continued to suffer joint pain and malaise. The lesions spread, developing on his face, legs and trunk, becoming painful, confluent and violaceous, with a deeper red desquamating rash on the medial planter area of both feet. He became cushingoid and hypertensive, BP 140/90mmHg. He was flushed, afebrile with no other peripheral stigmata of vasculitis. His CRP increased from 15 to 60 mg/L and he had a normocytic anaemia Hb 9-10g/dL. Methotrexate was increased to 25mg weekly and prednisolone to 30mg daily. The SoJIA diagnosis was re-examined and differentials of infection, neoplastic, para-neoplastic, and periodic fever syndromes were again excluded. Biopsy of the rash showed medium vessel vasculitis with fibrinoid necrosis. Methotrexate was withheld at patient request. Rapid clinical improvement followed. Joint pain settled, energy levels increased, skin lesions became flattened and less painful, resolving over four weeks. Background: Dermatomyositis exhibits around a dozen different clinical patterns of rash, incorporating perhaps twenty-five particular physical signs to look for. Mucinous dermatomyositis, where florid clinical mucin deposition is part of the overall pattern is uncommon, but a single plaque of mucin deposition is probably one of the rarest physical signs. We describe a patient who presented with such a plaque whose disease was only appreciated when the SAE1 myositisspecific ENA came back positive. Methods: A 68 year old female gave a two week history of painful, stiff hands that was mis-diagnosed elsewhere as polymyalgia rheumatica. Systemic steroids produced a good response after two weeks and she was weaned off after nine months, with no recurrence. One week after stopping the medication she developed a large, painful, tense, erythematous, oedematous plaque across the lower abdomen with a peau d'orange appearance. Histology revealed extensive mucin deposition throughout the dermis with a mild perivascular lymphocytic infiltrate, suggesting, after the exclusion of secondary causes, a diagnosis of primary localized cutaneous mucinosis. There was a strong family history of colonic polyps and cancer. Our patient had had four benign polyps removed a few years previously but regular screening had revealed nothing since then. Results: Screening for myositis-specific ENA was included as part of the workup for inflammatory polyarthritis, and the SAE1antibody was strongly positive. Her muscle strength was normal as was the serum creatine kinase; MRI of the thigh muscles was negative for myositis. The ANA was positive at 1/160 but anti-synthetase and ENA antibodies were negative. Further clinical examination revealed, slightly oedematous hands and fingers, early mechanics hands, faint heliotrope eyelids and a suggestion of mucin deposition over the shoulders. The plaque had begun to involute spontaneously but this seemed to accelerate with the introduction of hydroxychloroquine 200mg daily. Conclusion: Like lupus erythematosus, some increase in dermal mucin is seen in dermatomyositis but if present in the papillary dermis in markedly increased amounts, vesicles and bullae become the dominant features of the widespread rash. Multiple plaques of mucinosis, with mucin in reticular and papillary dermis, are rare though well recognized. The presence of a single plaque is even rarer. One report describes a similar large plaque, also on the lower abdominal wall, although the appearance there was more corrugated than peau d'orange-like. The SAE1 antibody is found in 6-8% of adult Caucasian patients with dermatomyositis. This antibody is supposed to confer a lower risk for, or at least a delayed onset of, myositis, as well as a lower risk for internal malignancy. She has no clinical or investigational evidence for myositis nor for internal malignancy despite being at very high risk for colon cancer. She continues to be screened for that regularly. 
METHOTREXATE-INDUCED VASCULITIS IN A CHILD WITH SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
AN UNUSUAL CAUSE FOR KNEE EFFUSIONS IN A TEENAGER FROM AFGHANISTAN
Susan Wang and Margaret Callan Rheumatology, Chelsea and Westminster Hospital, London, UNITED KINGDOM Background: A 14 year old Afghani teenager, who came to the UK as a refugee, presented with a 2 year history of worsening bilateral painful, swollen knees and ankles. He also had increased thickening of the skin on his face and hands giving the appearance of premature ageing. Methods: Examination revealed severely swollen knees with large effusions, thickened wrists and ankles, finger clubbing and coarse skin folds on the face suggestive of leonine facies. He was investigated with imaging, knee aspiration and blood tests. Results: Plain X-rays of the hands, wrists and lower limbs showed cortical thickening and periostitis in all the bones imaged. MRI of the knees demonstrated large bilateral effusions. Knee aspirate was acellular in the left knee, 1þ white cells in the right knee, with no crystals and no growth on culture. Blood tests showed an acute phase reaction with CRP 50 and ESR 38. The WCC was 5.5 with neutrophils of 3.1. Hb was 115 on first review but subsequently dropped to 76. The patient reported prior intermittent episodes of anaemia. OGD demonstrated duodenal ulceration. Albumin was reduced at 31. ANA, ANCA, anti-CCP and RF were all negative. Complement C3 and C4 were normal. Infective causes including TB and leprosy were tested for and ruled out. The appearance of the bones and young age of onset suggested a genetic disorder. A PubMed search using the key clinical features of knee effusions, finger clubbing, thickened bones and leonine facies led to a clinical diagnosis of primary hypertrophic osteoarthropathy (PHO), a rare genetic disorder affecting the prostaglandin pathway. The patient underwent genetic testing for known mutations associated with PHO. He was homozygous for a mutation in SCLO2A1, a gene which encodes a prostaglandin transporter and results in elevated levels of prostaglandin E2. Conclusion: The first described case of SCLO2A1 mutation causing PHO was in 3 Chinese families in 2012. Subsequent case-reports have documented individuals in Japan, India and Pakistan. This is the first case reported of an SCLO2A1 mutation in the Afghan population. SCLO2A1 gene mutations have also been described in hereditary enteropathy involving nonspecific gastrointestinal ulceration without skeletal manifestations. Unusually, this patient had features of the gastrointestinal as well as the cutaneous and musculoskeletal manifestations associated with SCLO2A1 mutation. Background: The risk of uveitis in patients with psoriatic arthritis (PsA) is well documented however, the magnitude of risk of uveitis and inflammatory bowel disease (IBD) in people with PsA or psoriasis is less consistent in the literature. The aim of this study was to calculate the incidence and prevalence of uveitis and IBD in patients with PsA and psoriasis alone and compare this with the general population in the UK. Methods: Incident cases of PsA, aged 18-89 at time of diagnosis, were identified from the Clinical Practice Research Datalink, 1998-2014 using Read codes and prescription data. Cases of PsA were matched by age, sex, general practice, and the date of the PsA diagnosis (index date) to two randomly selected cohorts: patients with psoriasis only and a general population cohort with no PsA or psoriasis. Prevalent cases of uveitis and IBD had an earliest date of diagnosis on or before their index date; incident cases were those with a first date of diagnosis after their index date. Incidence Rate Ratios of uveitis and IBD in psoriatic disease compared with the general population were calculated using Poisson regression.
Results: There were 6,783 (49% males) incident cases of PsA that were matched to 27,132 patients with psoriasis and 27,132 patients from the general population. The mean age at PsA diagnosis was 49.2 years. The prevalence on the index date, and incidence rates of uveitis and IBD in the study population are shown in Table 1 . The incidence of uveitis was significantly higher in patients with PsA and with psoriasis than in the general population. The incidence of Crohn's Disease, but not Ulcerative Colitis (UC) was higher in patients with PsA than in the general population but not in patients with psoriasis alone. Conclusion: In this large population based study we report an increased risk of developing Crohn's Disease, but not UC, among patients with PsA. We also report an increased risk of developing uveitis among patients with PsA over those with psoriasis alone or the general population. Results: Within the CPRD 88,858 incident psoriasis (48.6% male) and 6783 incident PsA patients (49.0% male) were identified. The incidence of psoriasis and PsA was 182.8 (95% CI 181.6,184.0) and 13.4 (95% CI 13.1,13.8) per 100,000 person-years respectively. The average duration of follow-up was 5.8 years. Within the incident psoriasis cohort, the incidence of PsA was 270.7/100,000 personyears (95% CI 256.9, 285.0). Of the CPRD PsA patients, 5,272 (77.7%; 2,652 males) had a record of psoriasis. The Bath cohort included 815 patients with data on both the year of psoriasis and PsA diagnosis. The mean age at PsA diagnosis was 49.2 years in the CPRD and 42.0 years in the Bath cohort. In the CPRD, the majority of patients had a psoriasis diagnosis before their PsA diagnosis (82.3%) or synchronously within the same calendar year (10.5%), with only a minority receiving their PsA diagnosis code first (7.1%). In the Bath cohort, 61.3% presented with psoriasis before their PsA, 23.8% presented within the same calendar year and 14.8% presented with arthritis first. Excluding those who presented with arthritis before their psoriasis, the mean time interval between diagnoses was 10.8 years [SD 10.9; median 8 (IQR 2-15)] in the CPRD and 11.8 years [SD 13.2; ] in the Bath cohort. Among the CPRD patients, 60.1% received their PsA diagnosis within the 10 years after their psoriasis diagnosis and 75.1% within 15 years. This was comparable with the Bath cohort at 57.2% within 10 years and 67.7% within 15 years. Conclusion: The larger proportion of patients receiving their PsA diagnosis before or synchronous with their psoriasis diagnosis in the Bath hospital-based cohort reflects in part the differences in recording and the nature of the healthcare settings. Although the majority in both cohorts receives a diagnosis of PsA within 10 years of the diagnosis of psoriasis, there was a significant proportion who did not, which may have implications for screening strategies. Biochemistry, King George Medical University, Lucknow, INDIA Background: The TNFSF4 gene (located at chromosome 1q25) encodes for TNFSF4 (also known as OX40L protein), a cytokine involved in T-cell and antigen presenting cell (APC) interactions. Increased levels of TNFSF4 lead to increased activation of T and B cells, hence, predisposing to systemic lupus erythematosus (SLE). Single-nucleotide polymorphisms (SNPs) in the TNFSF4 gene have been shown to be associated with SLE in European and Chinese populations. We aimed to verify the association of TNFSF4 polymorphism (rs2205960) with SLE in North Indian population and to study the genetic relations between this SNP and sub-phenotypes of SLE. Methods: 306 SLE patients and 480 controls were enrolled. All samples were genotyped for SNP rs2205960 using TaqMan genotyping assay in a Roche LC480 real-time polymerase chain reaction (PCR) system. A case-control association study and a genotype-phenotype correlation were performed. Results: The mean age of the SLE patients was 30.7 years and 94.4% were female. Allelic and genotypic frequencies did not deviate from Hardy-Weinberg equilibrium in the controls (p > 0.05). Allele contrast showed that the variant allele T was associated with increased risk for SLE when compared with the G allele [OR 1.28 (95% CI 1.02, 1.62), P ¼ 0.039]. A significant difference was also detected under a dominant model with regard to the distribution of genotype frequencies between SLE patients and healthy controls [(TT þ GT) vs GG: OR 1.37 (95% CI ¼ 1.03, 1.82), P ¼ 0.034], while no association was observed between SNP rs2205960 and any of the clinical manifestations of SLE. Conclusion: A single nucleotide polymorphism rs2205960 in TNFSF4 predisposes to SLE in North Indian population. Our results are in accordance with previous studies conducted in European and Chinese populations, indicating that the TNFSF4 gene might be a common genetic factor associated with SLE in multiple ethnic groups. Disclosure statement: R.M.: Grants/ research support: Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow (intramural grant). V.G., A.P., S.K., R.S. and A.A. have declared no conflicts of interest.
QUANTITATIVE OUTCOME MEASURES FOR SYSTEMIC
Background: Image annotation software allows tracking of nailfold capillaroscopic changes over time and could therefore potentially provide outcome measures for systemic sclerosis (SSc)-related microangiopathy. The objective was to assess repeatability (a prerequisite for outcome measure adoption) of image acquisition and measurement. Methods: 123 patients [101 SSc, 22 primary Raynaud's phenomenon (PRP)], and 50 healthy controls (HC), underwent high-magnification (300Â) videocapillaroscopy mosaic imaging of 10 digits (1730 images). One week post-baseline 41 patients (26 SSc, 15 PRP) and 10 HC returned for repeat imaging. Images from baseline and 1 week visits were assessed in a random order by an expert observer blinded to the image's origin (patient/finger/time-point). Custom software was used to assess images and extract 4 outcome measures: the image was graded overall and then (where possible) distal vessel locations were marked, allowing vessel density (across the whole nailfold) to be calculated. Each marked vessel was subsequently characterized, with the number of giant vessels counted and apex width measured. We examined the intra-rater, intra-visit (test-retest) reliability to understand the variability introduced solely by the observer (assessing the same image twice), and the intra-rater inter-visit (baseline vs. 1 week) reliability as a proxy for the reproducibility of the image acquisition/ measurement process combination (assuming that within 1 week the microvasculature will not change). A linear, mixed-effects model was used to estimate variance components, from which intra-class correlation coefficients were determined. Results: 1614 images at baseline and 641 at 1 week were fully marked-up (>1 vessel identified/characterized/measured). A total of 392 images had evaluations at both baseline and 1 week. The intrarater reliability estimates are shown in Table 1 . Conclusion: The reliability for the single observer is excellent for 3 out of 4 measures when viewing the same image, and remains so for 2 out of 4 (width and overall grade) when comparing 1 week image outcomes to baseline. This suggests that both image analysis and acquisition are reproducible, and that quantitative nailfold capillaroscopy, at least with a single observer, provides reliable outcome measures for clinical studies including randomized controlled trials. Rheumatology, New Cross Hospital, Wolverhampton, UNITED KINGDOM Background: Polymyositis is an idiopathic inflammatory myopathy characterized by proximal muscle weakness and inflammatory infiltrates in muscle tissue. Only 14% of such cases occur during childbearing age. Therefore, pregnancy-associated cases are rare and little is known regarding the effects of polymyositis on pregnancy and vice versa. Methods: We reported a 31-year-old pregnant woman who presented with respiratory failure due to polymyositis during her first pregnancy. Results: A 31-year-old woman in her 18th week of pregnancy presented with four months history of progressive dyspnea, orthopnea and significant proximal muscle weakness, which all initially attributed by her primary-care physician as pregnancy related. On admission she presented with type-2 respiratory failure. Examination revealed proximal muscle weakness with grade 3/5 in upper and lower limbs with weakness in neck flexion. There was no skin rash with normal peripheral sensations. Breathing sounds were normal, but with weak respiratory effort. She required intubation with mechanical ventilation. She has been investigated for causes of acute respiratory failure and muscular weakness. She has negative test for myasthenia graves (pyridostigmine test). CSF analysis, MRI of the head and spine and CT angiography of the chest were all normal. We made provisional diagnosis of polymyositis based on history, examination, raised CK (2338 U/L). Later on, EMG, thigh muscles MRI and Muscle biopsy confirmed the above diagnosis. The patient received 500 mg of IV Methylprednisone daily for 3 days with good initial response; she was extubated but needed on and off BiBAP support for the next 3 weeks. Then we started her on reducing doses of oral prednisolone 1mg/kg. She also received IV Ig (0.4g/kg daily over 5 days) every 6 weeks to control her disease during pregnancy as she developed side effect with Azathioprine. We elected to use this IV Ig regimen to avoid fluid overload. On discharge, the patient was well, with improved muscle weakness, resolving of her SOB and normalization of her CK. She has been followed in our specialized rheumatology pregnancy clinic and the high risk obstetric clinic. Foetal status was good but is small for gestational age, accordingly her delivery induced at 31 week as suggested by the team and her serial foetal US findings. The baby weighed 1160 g with no congenital malformation. Currently, she is in remission on prednisolone 5 mg daily and her CK continued to be within normal limit. Conclusion: Complaints of muscle weakness and dyspnea should not be dismissed as symptoms of pregnancy alone and should be investigated. We believe that early diagnosis, management with multidisciplinary approach and serial US assessment of the foetus are essential for good outcome. Use of IV Ig to control the disease is safe during pregnancy. Disclosure statement: The authors have declared no conflicts of interest. Background: The anti-synthetase autoantibody is the most common in adult patients with dermatomyositis (DM). In the pediatric population, anti-synthetase autoantibodies are rare and found in less than 5% of patients with Juvenile DM (JDM) but occur in 9% of patients with JPM and 13% of patients with juvenile overlap myositis, with the peak age at disease onset being 14 years. The aim of this study was to define the frequency and investigate the clinical associations of antisynthetase autoantibodies in a large cohort of patients with JDM, the UK JDM Cohort and Biomarker Study (JDCBS).
ANTI-SYNTHETASE AUTOANTIBODY IS SEEN IN PATIENTS WITH OVERLAP MYOSITIS IN THE UK COHORT OF PATIENTS WITH JUVENILE DERMATOMYOSITIS
Methods: Serum samples and clinical data were obtained from 470 patients with JDM recruited to the UK Juvenile Dermatomyositis Cohort and Biomarker Study. The presence of anti-synthetase autoantibodies was determined by immunoprecipitation. Due to the small number of patients with the autoantibody in the study, descriptions of common features are given. Results: Anti-synthetase autoantibodies were identified in only 6 (1.3%) patients with JDM within the cohort. All patients were female and considered to have JDM overlap. 60% were of black origin. The details of their diagnoses and clinical features are demonstrated in Table 1 . Conclusion: Anti-synthetase autoantibodies can be identified in a small proportion of patients with JDM and identify a distinctive clinical sub-group. Screening for anti-synthetase autoantibodies at diagnosis would be useful to guide further investigation for lung disease and to look for overlap features. Disclosure statement: The authors have declared no conflicts of interest. Only one Pol3-positive patient (out of 50) had pulmonary fibrosis. Pol3-positive patients had the highest rate of renal involvement (20%) (p ¼ 0.026). ACA-positive patients had the lowest rates of organ involvement. Out of 20 patients, only one had pulmonary fibrosis (5%), one had pulmonary hypertension (5%) one had muscle involvement (5%), and none had renal or cardiac involvement. Digital ulcers or pitting scars were more common in TOPO-positive (51.6%) and ACApositive (45%) patients compared to Pol3-positive patients (22%) (p ¼ 0.003).
TREATMENT DECISIONS FOLLOWING A DIAGNOSIS OF CANCER DURING TUMUOR NECROSIS FACTOR INHIBITOR TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
Conclusion:
In this large multinational cohort of patients with early dcSSc, tOPO-positive patients present more often with pulmonary fibrosis than Pol3-positive and ACA-positive patients and had the highest prevalence of digital ulcers/pitting scars; Pol3-positive patients tend to exhibit more severe skin fibrosis and have a predisposition towards renal involvement but much lower rates of pulmonary fibrosis and positive ACA is seen in diffuse as well as limited SSc and is associated with a low prevalence of internal organ involvement. 
LIMITED CUTANEOUS SYSTEMIC SCLEROSIS SKIN DEMONSTRATES MOLECULAR SUBSETS THAT INCLUDE A CARDIOVASCULAR DEVELOPMENT GENE EXPRESSION SIGNATURE
Emma Derrett
Department of Clinical Sciences and Community Health, University of Milan, Milan, ITALY
Background: Limited cutaneous SSc (lcSSc) is characterized by less extensive skin fibrosis but patients can develop major internal organ complications and vascular manifestations. Gene expression analysis of SSc biopsies has been used to define molecular subsets of the disease and provide mechanistic insight into pathobiology. Clinically uninvolved skin in the diffuse cutaneous subset has closely replicated gene expression signatures compared with biopsies from clinically involved skin and a number of vasoactive genes have been identified this way. We have investigated the gene expression abnormalities in the more prevalent lcSSc subset through detailed transcriptional analysis of skin biopsies taken from uninvolved forearm skin. Methods: Total RNA was extracted from skin biopsies from 15 patients with SSc fulfilling 2013 EULAR/ACR classification criteria with the limited subset of disease and 8 healthy controls (HC). Demographic, clinical and serological parameters were representative of the recruitment cohort but purposefully broad. Gene expression profiling was performed on a DNA oligonucleotide microarray chip. Differentially expressed genes (DEG) were identified using Significance Analysis of Microarrays (SAM). Functional enrichment analysis of gene signatures was done via g:Profiler.
Results: There were 218 DEG between lcSSc and HC samples (False Discovery Rate <10%). 181/218 DEG were upregulated in lcSSc samples. Hierarchical clustering of DEG suggested the presence of 2 separate groups of lcSSc samples: limited 1 and limited 2. The limited 1 group (13 samples, 10 unique patients) showed upregulation of genes involved in cell adhesion, cardiovascular system (CVS) development and extracellular matrix as well as immune and inflammatory response. The CVS development signature was of particular interest as its genes showed very strong enrichment in response to wounding, response to TGF-b and kinase cascade. Sample genes included ANGPT1, COL4A1, FBN1, SERPINE1, THBS1 and CCL2. Neither limited 2 group (6 samples, 5 unique patients) nor HC samples showed functional enrichment. There were no significant differences in demographic or clinical parameters between these two groups including the presence of significant microvascular involvement and hallmark antibody reactivities. Conclusion: Our study suggests the presence of molecular subsets in lcSSc that overlap with other clinical and serological features based on gene expression profiling of biopsies from uninvolved skin. This may reflect important differences in pathogenesis within these patient groups. We identify differential expression of a subset of genes that relate to CVS and are enriched in fibrotic signalling. This may shed light on underlying mechanisms of vascular disease in SSc. The enrichment in profibrotic profile is striking and suggests that dysregulated gene expression may contribute to vasculopathy and fibrosis in different disease subsets. Disclosure statement: The authors have declared no conflicts of interest. Background: Recent studies of phosphodiesterase type 5 (PDE5) inhibitors have shown varied clinical benefit in patients with Raynaud's phenomenon. This audit aimed to examine the use of the PDE5 inhibitor sildenafil following its off-patent availability and to investigate whether its repositioning in the management of patients with digital vasculopathy will maximize efficiency and reduce costs in treating digital vasculopathy. Methods: Patients with Raynaud's phenomenon, critical digital ischaemia or digital ulceration were identified using medical records at Aintree University Hospital Trust. Patients who received a prescription of iloprost or sildenafil from 1 April 2012 to 31 December 2015 for the management of Raynaud's phenomenon, critical digital ischaemia or digital ulceration were included. A sub-population was selected from these patients; those who were prescribed sildenafil between 1 October 2014 and 31 March 2015. Patients under 16 years of age and patients with pulmonary artery hypertension were excluded. Outcome measures used were: the number of iloprost prescriptions before and after generic availability of sildenafil and the outcome of sildenafil treatment on Raynaud's symptoms, digital ulcer healing and iloprost requirement.
REPOSITIONING SILDENAFIL IN RAYNAUD'S: A REAL-WORLD EXPERIENCE
Results: There was a 27% decrease in the number of prescriptions of iloprost when comparing the 2 years pre and post generic sildenafil adoption on the treatment pathway. A sub-population of 34 patients who received sildenafil as a new prescription between 1 October 2014 and 31 March 2015 were identified: these subjects' clinical records were reviewed in detail to 31 December 2015. 68% of these patients reported that the number and duration of Raynaud's attacks were slightly or significantly better within 8-12 weeks of commencing sildenafil. 64% of patients with digital ulcers experienced healing of their ulcers while taking sildenafil. Approximately 50% of patients experienced some side effects on sildenafil, with headache and dizziness most commonly reported; most of these side effects were acceptable to the patients and sildenafil was continued in the majority. Conclusion: There has been a reduction in use of iloprost since sildenafil became generically available that has led to a significant cost saving. Most patients noticed improvements in Raynaud's severity and digital ulcer healing following sildenafil use. A prospective study is recommended which uses a validated measurement instrument for digital vasculopathy severity before and after sildenafil use. A high quality study would help to set national guidelines on the use of sildenafil in digital vasculopathy. Disclosure statement: The authors have declared no conflicts of interest. Background: Anti-centromere antibodies (ACA) typically associate with limited cutaneous subset (lcSSc). Only 5-7% of ACA-positive patients have the diffuse subset (dcSSc). Both antibody specificity and disease subset may influence disease phenotypic expression and organ manifestations, with ACA being protective for renal crisis and interstitial lung disease (ILD). The purpose of this study was to define clinical characteristics and long-term survival of patients with positive anti-centromere antibody and diffuse cutaneous systemic sclerosis (ACA-positive diffuse). Methods: Retrospective analysis of all cases of ACA-positive systemic sclerosis from a large referral centre (n ¼ 1313). Those ACA-positive diffuse patients were compared with representative groups of consecutive 158 patients ACA-positive with limited subset (ACA-limited) and 258 ACA-negative dcSSc (non-ACAdiffuse). Results: 36 ACA-positive patients (2.7%) had dcSSc. The peak modified Rodnan skin score was not significantly different between the diffuse groups, but occurred later in the disease course in ACApositive diffuse (88.54AE78.3 vs 30.6AE33.2 months, p < 0.001). Patterns of organ involvement were different between the groups. ACA-positive diffuse had higher incidence of interstitial lung disease (ILD) than ACA-positive limited (p ¼ 0.001), but significantly lower than non-ACA diffuse (p ¼ 0.042). Non-ACA diffuse developed ILD mostly in the first 5 years from disease onset, while it occurred later in ACA-positive diffuse. Similarly, incidence of SRC was higher in ACA-positive diffuse subjects (5.7%) compared to none among the ACA-positive limited ones, while marginally lower than that among non-ACA diffuse subjects (14%, p ¼ 0.280). More patients had pulmonary hypertension (PH) in ACA-positive diffuse (27.5% vs 12.0% -ACA-positive limited; 12.0% -non-ACA diffuse), though its cumulative incidence was not different between the three groups (p ¼ 0.621). Cardiac involvement was similar in both the dcSSc groups (6.2% -non-ACA diffuse vs 8.6% -ACA-positive diffuse, p ¼ 0.484), while much less frequent in ACA-positive limited patients (1.9%, p ¼ 0.074 from comparison with ACA-positive diffuse). Survival in ACA-positive patients was similar for both subsets with survival rates at 5, 10 and 15 years of 96%, 85% and 74% in ACApositive limited and 94%, 79% and 71% in ACA-positive diffuse (p ¼ 0.99). Comparing with ACA-positive diffuse, non-ACA diffuse had lower survival of 84%, 72% and 55% at 5, 10 and 15 years respectively (p ¼ 0.165). Conclusion: ACA dcSSc is uncommon and has a distinct clinical phenotype, with a more insidious onset of skin and organ involvement. Even in dcSSC, ACA appears protective for organbased complications, namely ILD and SRC, and associates with a better survival than expected in dcSSc. Therefore ACA may act as a phenotype modifier in dcSSc, and this relationship needs to be explored further in larger prospective studies. Disclosure statement: The authors have declared no conflicts of interest. Methods: This was a double-blind, randomized, crossover, placebocontrolled study. Sixteen (6 fingertip, 10 extensor) DUs were each studied twice (one day apart): once with GTN and once with placebo ointment. The mean (SD) age of patients was 55.7 (17.3) years. The RP duration (mean, SD) was 16.7 (8.8) years and disease duration (from first non-RP clinical manifestation) was 14.5 (8.6) years. All the patients had a history of previous DUs, often requiring previous prostanoid infusions (n ¼ 11) and not uncommonly surgical debridement (n ¼ 8) for severe digital vascular disease. The majority of patients were receiving current vasodilatory treatment/s (n ¼ 14), most commonly with calciumchannel blockers (n ¼ 10), and with several patients receiving treatment with an endothelial receptor antagonist (n ¼ 3) or PDE5-inhibitior (n ¼ 1). Perfusion at the DU centre (DUCore) and periphery (DUPeriphery), as measured by laser Doppler imaging was performed before and immediately after ointment application, then every 10 minutes, up to 90 minutes post-application. We calculated the area under the response curve (AUC) and the ratio of peak perfusion to baseline, then compared these between GTN and placebo.
THE DISTINCTIVE CLINICAL PHENOTYPE OF ANTI-CENTROMERE ANTIBODY-POSITIVE DIFFUSE SYSTEMIC SCLEROSIS
REDUCED PERFUSION IN SYSTEMIC SCLEROSIS DIGITAL ULCERS (BOTH FINGERTIP AND EXTENSOR) CAN BE INCREASED BY TOPICAL APPLICATION OF GLYCERYL TRINITRATE
Michael
Results: Perfusion was lower in the DUCore compared with the DUPeriphery (ratio of 0.52). The microvessels of the DUCore were responsive to GTN, with an increase in perfusion. The AUC and peak/baseline perfusion difference in means (ratio, 95% confidence interval) between GTN and placebo at the DUCore were 1.2 (1.0, 1.5) and 1.2 (1.0, 1.5) respectively, and at the DUPeriphery were 1.1 (0.7, 1.6) and 1.0 (0.8, 1.2) respectively. Both fingertip and extensor DUs responded similarly. The AUC and peak/baseline perfusion difference in means for fingertip DUs (DUCore) was 1.2 (1.0, 1.5) and 1.2 (1.0, 1.4), and for extensor DUs was 1.2 (0.8, 1.9) and 1.2 (1.0, 1.6). Conclusion: Our data confirm that DU centres are ischaemic. The microvessels of both fingertip and extensor DUs were responsive to GTN compared to placebo, particularly in the relatively ischaemic DU centre. Further research is warranted to understand the ischaemic drive to the formation of all DUs, including extensor aspect DUs, and whether this is potentially reversible (including through topical NO donation). This has important treatment implications, including on the design of future clinical trials, because our findings suggest that extensor as well as fingertip DUs should be included in studies of vasoactive therapies. Disclosure statement: The authors have declared no conflicts of interest. Background: Locally acting, well-tolerated treatments for digital ulcers (DUs) in patients with systemic sclerosis (SSc) are needed. Our primary aim was to investigate the safety, feasibility and tolerability of a novel light treatment. A secondary aim was to tentatively assess treatment efficacy.
A FEASIBILITY STUDY OF A NOVEL LIGHT TREATMENT FOR DIGITAL ULCERS IN SYSTEMIC SCLEROSIS
Methods: A custom built device was constructed consisting of infrared, red and blue light-emitting diodes. Treatment was administered twice weekly for three weeks, with follow-up at weeks 4 and 8. Any safety concerns were documented at each visit. Patient opinion on the time to deliver, feasibility (not feasible, indifferent, feasible) and pain visual analogue scale (VAS) scores (0-100, 100 most severe) with light treatment was collected. Patient and clinician DU VAS scores (0-100, 100 most severe) were documented. An independent assessor graded the change in DU appearance from photographs À2 (much worse) to þ 2 (much better)]. DU laser Doppler (perfusion) imaging was performed immediately before and after treatment at the DU centre (DUCore) and surrounding tissue (DUPeriphery). ClinicalTrials.gov identifier: NCT02472743. Results: 14 DUs in 8 patients (7 female and 1 male) were studied. The mean (SD) age of patients was 48.5 (15.2) years. Raynaud's phenomenon (RP) duration was 16.1 (11.7) years and disease duration (from first non-RP clinical manifestation) was 11.9 (7.6) years. Two patients had severe finger contractures. The majority of patients had a history of severe digital vascular disease, including previous intravenous vasodilator therapy (n ¼ 6) and previous surgical debridement (n ¼ 3). Almost all patients (n ¼ 7) were receiving treatment with vasodilatory drug therapy. Forty-six light treatments were administered, with no safety concerns. All patients considered light treatment was feasible and took just the right amount of time, with a low associated mean pain VAS of 1.6 (SD 5.2). Patient and clinician DU VAS scores improved during the study (mean change À7.1 and À5.2, respectively, both P 0.001). Independent assessment of the mean change in DU appearance per week was 0.14 (P ¼ 0.01). There was a significant increase in perfusion after light treatment: mean increase 0.32 (95% CI 0.13, 0.0.52; P ¼ 0.0013) at the DUCore and 0.15 (0.0, 0.30) (P ¼ 0.04) at the DUPeriphery. Conclusion: Light treatment for DUs is safe, feasible and well tolerated. There was an early suggestion of treatment efficacy, with a significant improvement in DUs during the course of the study and a local increase in DU perfusion with light treatment. Future research is warranted to develop light-based treatment as a locally acting therapy for DUs in patients with SSc. (SSc) . This study aimed to examine these different parameters along with measures of oxidative stress (OS) and oxygenation (OX), both implicated in SSc pathogenesis, in a cross-sectional study, as a first step in exploring inter-relationships. Methods: Skin thickness measurements (US images) were taken from 9 sites of the body (digit, dorsum of hand, forearm, upper arm, face, chest, abdomen, lower leg, dorsum of foot). Capillary density and width (NC images, non-dominant ring finger) were calculated using automated software. Perfusion images (dual wavelength LDI: green ¼ superficial capillary, red ¼ deeper thermoregulatory microcirculation layers) were taken of the hand pre and post local heating. Distal dorsal difference (DDD, digit-dorsum) was calculated at baseline and perfusion increase (POST/PRE) calculated at the digit and dorsum. Oxidative stress (OS) measurements (spectroscopy) were taken with UV-and oxygenation (OX) with white-light at US sites. Between group comparisons (ANOVA) were made with STATA. Results: 92 patients with limited cutaneous SSc (lcSSc), 47 with diffuse cutaneous SSc (dcSSc), 31 with PRP, 35 with undifferentiated connective tissue disease (UCTD), 61 healthy controls (HC) were assessed. Data are presented in Table 1 . US showed increased thickness at 8/9 sites for SSc vs HC (all sites except lower leg). NC density was lower and width higher in the SSc vs HC group. LDI showed lower DDD [thermoregulatory layer (red)] and POST/PRE digit and dorsum (both layers) for SSc vs HC. OS was significantly increased in 7/9 sites in SSc vs HC groups (all sites except digit and face). OX was lower at the digit but overall showed no trend for increase or decrease across the 9 sites in SSc vs HC group. Conclusion: Data confirm increased skin thickness, together with microvascular structural and functional changes and increased free radical stress (OS) in SSc in a large data set. Changes need to be measured prospectively and these studies are under way. Disclosure statement: The authors have declared no conflicts of interest. . Twenty-nine patients had more than one type of flare in the nine months: severe and mild (n ¼ 12), moderate and mild (n ¼ 14) and severe, moderate and mild (n ¼ 3). Twenty-four patients did not experience any A or B flares. The median time to any A or B flare was 4 months (95% CI 2.7, 5.3). At least 22% of all patients had a mild/moderate/severe flare by one month, 22% of all patients had a moderate/severe flare by 3 months and 22% of all patients had a severe flare by 7 months. The BILAG 2004 system/s that had A and/or B flares at baseline were as follows: constitutional (7.7%), mucocutaneous (21.8%), neuropsychiatric (2.4%), musculoskeletal (39.4%), cardiorespiratory (13.5%), gastrointestinal (2.4%), ophthalmic (1.2%), renal (11.8%) and haematology (0%). The system/s affected at baseline were compared to those affected at the time of the first severe, moderate and mild flares. Severe (13.6% discordant) and moderate (5.3% discordant) flares tend to be in the same system/s affected at baseline whereas mild flares are more likely to affect any system (34.3% discordant).
TABLE 1. LDI, spectroscopy (E, OX, OS) and NC data [median (IQR)] at the digit and dorsum of the hand
Technique Parameter HC (n ¼ 61) PRP n ¼ 31 UCTD (n ¼ 35) lcSSc (n ¼ 92) dcSSc (n ¼ 47) P-
Conclusion:
The results of this study will add to the knowledge on the frequency and severity of flares occurring in a real world population following the initiation of therapy to treat a flare. This population will have similarities with those entering clinical trials and the information may be useful for designing clinical trials. Background: Subacute cutaneous lupus erythematosus (SCLE) and drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) can be difficult diagnoses to make. Distinguishing one from the other can be even more challenging. Careful history taking is key to teasing out potential drug culprits which may in turn lead to complete resolution of a potentially disabling condition. Methods: We present the case of a 76 year old lady who presented to our department in March 2015 with a new-onset rash from September 2014. She had been referred by her GP with a scaly, erythematous, mildly itchy annular rash on her face, arms, chest, back and ankle. The GP treated the rash with topical steroid leading to some improvement. When seen in our department she had a non-specific papulosquamous eruption on her neck, chest and forearms. Her hands were not involved. No systemic symptoms were noted. There was no history of response or reaction to sun exposure. Of note, in January 2014, she had a possible transient ischaemic attack (TIA). Prior to this event, she was taking only taking Ramipril and Aspirin. After TIA clinic review in July 2014 she was commenced on Clopidogrel, Simvastatin and Lansoprazole. Blood tests were taken and a biopsy was performed. These revealed a positive ANA (speckled pattern) and anti-SSA (Ro). No other abnormalities were noted. The biopsy demonstrated a perivascular and lichenoid tissue reaction with an element of spongiosis and possible lymphocytic vasculitic component. The direct IMF showed granular deposition of IgG/IgA/C3/Fibrinogen at the dermal-epidermal junction. Results: With these results, the differential diagnosis included SCLE and DI-SCLE. The differential of classical drug induced lupus erythematosus was excluded as there were no systemic symptoms and a speckled, rather than homogeneous, pattern ANA was found. It is known that DI-SCLE does not differ clinically, histopathologically or immunologically from idiopathic SCLE. Lansoprazole is known but rarely reported cause of DI-SCLE. Therefore it was stopped. Two weeks after cessation, the rash cleared completely and topical treatment was stopped, therefore consistent with the diagnosis of DI-SCLE. Conclusion: DI-SCLE can be indistinguishable from idiopathic SCLE. There is some controversy with this statement and it is important to note that some clinicians feel that patients with DI-SCLE typically have more widespread and atypical eruptions (i.e. EM-like, vesicobullous and vasculitic rather than a papulosquamous annular eruption). Nevertheless, drug withdrawal is required to make the diagnosis of DI-SCLE and is typically the only treatment required. Carefully history taking and a working knowledge of likely drug culprits allow a clinician to make the diagnosis of DI-SCLE and effectively treat the affected patient. Disclosure statement: The authors have declared no conflicts of interest.
USTEKINUMAB IS EFFECTIVE IN TREATING PSORIATIC SPONDYLITIS: REAL-WORLD DATA FROM PATIENTS TREATED FOR PERIPHERAL PSORIATIC ARTHRITIS
Antoni Chan, Linda Herdman, Kathryn Rigler and Susan Hicks Department of Rheumatology, Royal Berkshire NHS Foundation Trust, Reading, UNITED KINGDOM Background: Ustekinumab is an interleukin (IL)-12/IL-23 monoclonal antibody that has been shown to be effective in treating psoriasis and psoriatic arthritis (PsA). PsA affects the peripheral joints but can also involve the spine/axial skeleton in 25-75% of patients with PsA. Spondylitis in PsA is commonly associated with peripheral arthritis.
This study aimed to evaluate the effect of Ustekinumab on spondylitis scores in PsA patients. Methods: All patients who met the CASPAR criteria for PsA were included in this study. Patients on Ustekinumab for PsA between June 2015 (time of NICE approval) and October 2016 were identified and included in this study. 12 patients were identified (males ¼ 5, females ¼ 7) and included in this study. Patients received Ustekinumab 45mg or 90mg based on weight, at week 0, 4 and every 12 weeks thereafter. Physician identified spondylitis was evaluated by using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score using C-Reactive Protein (ASDAS) and the Spinal Pain Visual Analogue Scale (Spinal VAS). Assessments were done at baseline and at Week 24 together with the Psoriatic Arthritis Response Criteria (PSARC) score. The PSARC score consist of 68 tender joint, 66 swollen joint count, patient and physician global assessments (0-5). Results: The median age was 54.5 years and mean PsA disease duration was 7.5 years. The mean number of DMARDs used prior to Ustekinumab was 3. 10 patients had at least one anti-TNF agent prior to commencing Ustekinumab. 2 patients were bio-naïve due to contraindication to anti-TNF agents. The mean number of tender joints was 15.6 (SD 11.6), swollen joints 11.5 (9.6), patient global 4.1 (0.7) and physician global 3.9 (0.7). Comparing baseline results to assessments at week 24, there were improvements in the mean BASDAI score by 35.3%, ASDAS by 31.5% and Spinal VAS by 25.6%. The BASDAI had improved from baseline of 6.3 (1.9) to 4.1 (2.8), ASDAS from 4.1 (1.9) to 2.8 (2.1) and Spinal VAS from 6.6 (1.8) to 4.9 (2.2). All patients had an improvement in at least 2 of the 4 criteria for the PSARC score. The mean number of tender joints had improved to 7.1 (6.4) and swollen joint to 3.8 (4.8) at Week 24. Conclusion: Ustekinumab is beneficial in improving spondylitis scores (BASDAI, ASDAS and Spinal VAS) in patients with physician-identified psoriatic spondylitis. This corresponds to the improvement in the peripheral arthritis joint scores. These real-world data in patients with well-established PsA supports the findings from previous studies. Further studies are needed to look at the radiographic change of axial spondylitis during treatment with Ustekinumab for psoriatic arthritis. Disclosure statement: The authors have declared no conflicts of interest.
INFLUENCE OF COMPONENTS OF METABOLIC SYNDROME ON THE COURSE OF PSORIATIC ARTHRITIS
Maruf Salohiddinov
Rheumatology and Osteopathy, Tashkent Medical Academy, Tashkent, UZBEKISTAN Background: This study defined the criteria of the metabolic syndrome (MS) and their connection with clinical course of psoriatic arthritis (PsA). Methods: The study involved 42 patients with PsA diagnosed based on the classification criteria of CASPAR. Average age of patients 36.52 AE 11.27 years, disease duration prior to enrollment 12.4 months (SD 9.2 months. 70.8% had PsA, 29.2% had interictal period. Statistical analysis of data is made using Student's t-test (level of reliability P < 0.05). control group consisted of 14 healthy men. Results: Among the 72 patients with PsA, MS was revealed in 46 (63.9%). MS criteria were: abdominal obesity (waist circumference OT ! 102 cm to 69.7%), hypertension (SAP!138, DAP!85 mmHg, 80.5%), hyperglycemia (HG ! 6,1 mmol/L in 20.8%), dyslipidemia: increased levels HS ! 190mg/dl, and 26.4% TG ! 150mg/dl, and also increase uric acid levels (MC) !360 umol/L, 63.9%, and the concentration a high-sensitivity (C-RP!5 mg/ml). In addition, 55.5% of hypertension were as follows concomitant diseases: coronary heart disease (CHD) (31.4%), diabetes mellitus type 2 (16.7%), chronic renal failure (12.5%), chronic heart failure (13.9%). Hypertension was associated with coronary artery disease in 34.7%, prior stroke in 11.2% myocardial infarction and 15.3%. It was found that obesity and hypertension was preceded by the development of PsA in 36 of 46 (78.3%) of patients with MS. Increasing the number of MS criteria contributed to the increase hyperuricemia and increase the number of afflicted joints was more severe course related diseases and their complications. Increasing of the concentration of CRP (15.2 AE 3.6 mg/ml versus 3.8 AE 0.6 mg/ml) were observed in patients with PsA with MS more frequent and prolonged exacerbations of PsA per year (4.2 AE 1.1), those without metabolic syndrome [2.1 (SD 0.8)] (P < 0.05). Conclusion: Psoriatic arthritis is often associated with metabolic syndrome, which complicates the clinical course of disease. Number of criteria of metabolic syndrome affects the severity of concomitant cardiovascular and renal disease. Increasing the concentration of CRP predicts frequent exacerbations of PsA. Disclosure statement: The author has declared no conflicts of interest. Background: Treatment goals for active psoriatic arthritis (PsA) include long-term control of both skin and joint symptoms. PALACE 3 (NCT01212770) included PsA patients with active joint disease and an active skin lesion at enrollment. Long-term treatment responses were assessed across PsA manifestations in patients receiving apremilast (APR) for 3 years. Methods: Patients were stratified by baseline DMARD use (yes/no) and psoriasis body surface area involvement (<3%/!3%) and randomized (1:1:1) to placebo, APR 30 mg BID (APR30) or APR 20 mg BID (APR20). After the 24-week placebo-controlled phase, all patients were treated with APR30 or APR20 and could enroll in long-term follow-up. Efficacy assessments were conducted over 156 weeks. Results: 505 patients were randomized and received !1 dose of study medication (placebo: n ¼ 169; APR30: n ¼ 167; APR20: n ¼ 169). A total of 89% (249/281) Table 1 . The MID for improvement using the anchor method for the RAPID3 was À8.1 (SD 5.9) and DAPSA À27.9 (SD 23.7). The MID using the ROC method for the RAPID3 was À5.1 (AUC 0.84) and DAPSA À16.7 (AUC 0.75). There is no significant difference between the response to treatment when measured by the RAPID3 and DAPSA for either the TNF (p ¼ 0.76) or DMARD (p ¼ 0.09) groups. Conclusion: RAPID3 is correlated significantly with other outcome measures and appeared more sensitive to change than the DAPSA in this study. We report an estimate of the MID and SDD of the RAPID3 in PsA. These data support the validity of the RAPID3 as a feasible and sensitive measure of disease activity in PsA.
28-JOINT DISEASE ACTIVITY SCORE REMISSION AND IMPROVEMENTS IN SKIN DISEASE OVER 3 YEARS OF TREATMENT WITH APREMILAST: RESULTS FROM THE PALACE 3 STUDY IN DISEASE-MODIFYING ANTI-RHEUMATIC DRUG/BIOLOGIC-EXPERIENCED ACTIVE PSORIATIC ARTHRITIS PATIENTS
069 Background: Up to 40% of patients with inflammatory arthritis on TNF-a inhibitor (TNFi) treatment fail to respond either due to primary inefficacy or loss of response. One explanation is immunogenicity leading to the development of anti-drug antibodies (ADAb) and subsequent low drug levels. Few data exist on whether such pharmacological tests correlate with treatment response in psoriatic arthritis (PsA). Our aim was to identify whether the presence of ADAbs/ drug levels predict treatment response and disability in TNFi-treated PsA patients, the factors associated with drug levels and a drug level threshold for optimal therapeutic response. Methods: 75 patients were available from the Outcomes of Treatment in PsA Study Syndicate (OUTPASS) (n ¼ 49 adalimumab; n ¼ 26 etanercept), a national UK prospective observational cohort. Serum samples were collected at 3, 6 and 12 months following initiation of TNFi therapy. ADAbs were measured using radioimmunoassay (RIA) and random (non-trough) drug levels using ELISAs at 3, 6 and 12 months. Disease activity (DAS28) scores were measured at each visit. Patient self-reported adherence to TNFi was measured at each timepoint. Generalized estimating equation (GEE) was used to test the association between ADAbs and drug levels, both biomarkers and treatment response as assessed by change in DAS28 score between pre-treatment and 12 months post-treatment (ÁDAS28), Health assessment Questionnaire (HAQ) and the association between longitudinal/baseline factors with drug levels. Results: 264 serial samples were suitable for pharmacological testing (n ¼ 174 adalimumab; n ¼ 90 etanercept). Mean age was 51AE12 years; 61% were female; median BMI 28.9 (IQR 26.0-34.9). 20% (n ¼ 10/49) of adalimumab-treated patients were positive for ADAbs, but none were detected in etanercept-treated patients. There was no significant association between etanercept drug levels and ÁDAS28 over 12 months Background: Fifty percent of patients with psoriatic arthritis are female. Most of these patients are of childbearing age at diagnosis. Foetal risks in pregnant women with psoriatic arthritis are derived both from maternal disease and the medications used to control the illness. The purpose of this study was to review the outcomes of the pregnant patients in our unit with psoriatic arthritis.
PSORIATIC ARTHRITIS AND PREGNANCY: A SINGLE CENTRE REVIEW OF PREGNANCY OUTCOMES
Methods: A retrospective analysis of all pregnant women with a diagnosis of Psoriatic Arthritis between 2013 and 2016 was conducted at the Mile End and Royal London Hospitals of Bart's Health NHS Foundation Trust. These patients were all referred by their primary Rheumatologist to the combined Rheumatology-Obstetric medicine clinic. Data were obtained via electronic records. Results: Between 2013 and 2016, there were 11 documented pregnancies in 9 women with psoriatic arthritis. Over 80% of patients had documented evidence of pre-pregnancy counselling prior to conception. The average maternal age in pregnancy was 32.7 years (26-36). Of the 11 pregnancies, one patient required in vitro fertilisztion. Mean number of previous pregnancies was 3. Mean length of time to booking in the pre-natal clinic was 11 weeks 3 days (9 weeks 2 days-12 weeks 4 days). Mean gestation was 38 weeks 4 days. Eight of the 11 deliveries were spontaneous (4 vertex, 4 instrumental delivery), 2 were elective caesarean section and 1 was a forced induction. In terms of complications related to the pregnancy, one patient developed gestational diabetes. One neonate suffered respiratory distress. With respect to disease activity, 8 patients went into remission of joint disease during pregnancy, 3 patients experienced a flare of their arthritis. 2 patients required brief hospitalization. 6 patients reportedly experienced a flare. In terms of treatments required during pregnancy, NSAIDs(1) oral steroids(5), intra-articular steroids (1) . DMARDs used in pregnancy include sulphasalazine(2), azathioprine (1), ciclosporin (1) . 2 patients required biologic therapy with anti-TNF. 1 patient required phototherapy for skin disease. Post-partum, 6 patients experienced a flare of inflammatory arthritis within 2 months of delivery, 2 patients had a flare of skin disease. Post-partum treatments; NSAIDs, prednisolone, sulphasalazine and methotrexate. 5 patients were restarted safely on biologics post breastfeeding. There were no significant adverse outcomes in any patients. Conclusion: Anecdotally, it is thought that psoriatic arthritis improves during pregnancy with a risk of flare post-partum. This would appear to be reflected in our cohort of patients. However, some patients experienced significant flares, requiring hospitalization and commencement on biologic therapy. As increasing confidence is gained with the use of biologics in pregnancy, this may be better avoided in the future. Overall, the outcomes of pregnancy in patients with psoriatic arthritis were favourable. This should give confidence to physicians when advising women during pre-pregnancy counselling. Disclosure statement: The authors have declared no conflicts of interest. (Table 1) . Responses were sustained through Week 104 in anti-TNF-a-naive and anti-TNF-a-IR patients: ACR20 response rates in anti-TNF-a-naive patients were 80.4%, 86.8% and 68.6% with 300, 150 and 75 mg, respectively; corresponding rates in anti-TNF-a-IR patients were 60.7%, 41.7% and 43.8%. Over the entire treatment period [mean (AESD) exposure to secukinumab of 709AE211 days] the incidence, type and severity of adverse events were consistent with those reported previously. Specifically, EAIR for serious infections/infestations, candida infections, inflammatory bowel disease, malignant/unspecified tumours and major adverse cardiac events with secukinumab were 1.6, 2.3, 0.5, 1.3 and 0.3, respectively. a PASI responses assessed in patients with psoriasis affecting !3% the body surface area at BL (300 mg, n ¼ 41; 150 mg, n ¼ 58; 75 mg, n ¼ 50); b Assessed in patients (300 mg s.c, n ¼ 56; 150 mg s.c., n ¼ 58 and 75 mg s.c, n ¼ 67) with this symptom at BL. c Assessed in patients (300 mg s.c, n ¼ 46; 150 mg s.c., n ¼ 32 and 75 mg s.c, n ¼ 33) with this symptom at BL. BL, baseline; DAS28-CRP, 28-joint DAS using CRP; HAQ-DI, HAQ disability index; LS, least squares; n, number of patients randomized; PASI, Psoriasis Area and Severity Index; SE, standard error; SF-36 PCS, 36-item Short Form Health Survey physical component summary.
SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 104 WEEKS RESULTS FROM
Background:
The PALACE 1 (NCT01172938), 2 (NCT01212757), and 3 (NCT01212770) studies compared the efficacy and safety of apremilast (APR) with placebo in patients with active psoriatic arthritis despite prior conventional disease-modifying anti-rheumatic drugs and/or biologics. We assessed long-term APR safety for up to 3 years. Methods: Patients were randomized (1:1:1) to receive placebo, APR 30 mg BID (APR30), or APR 20 mg BID (APR20). Placebo patients were re-randomized to APR30 or APR20 at Week 16 (early escape) or Week 24. Double-blind APR treatment continued to Week 52; patients could continue APR during an open-label treatment phase. Results: 1,493 patients were randomized; 1,441 patients had 0 to 52 weeks of APR exposure, 1,028 had >52 to 104 weeks of APR exposure, and 865 had >104 to 156 weeks of APR exposure at the 3-year data cut. During Weeks 0 to 52, adverse events (AEs) occurring in ! 5% of APR-exposed patients were diarrhoea, nausea, headache, upper respiratory tract infection and nasopharyngitis (Table  1) . Diarrhoea and nausea usually occurred and resolved without intervention early in treatment ( 2 weeks and 4 weeks, respectively). During Weeks >52 to 104 and >104 to 156, the frequency of gastrointestinal AEs decreased; other common AEs occurring in ! 5% of APR-exposed patients decreased in frequency or remained stable (Table 1) . Most AEs were mild to moderate in severity. The rate of serious AEs remained consistent across all 3 APR-exposure periods (Table 1) . Discontinuation rates decreased every year, reaching 1.6% during Weeks >104 to 156 (Table 1) . Major cardiac events, malignant neoplasms, opportunistic infections, and marked laboratory abnormalities remained infrequent throughout treatment. Conclusion: APR treatment demonstrated a favorable safety profile up to 156 weeks, marked by stable or decreasing AE incidence and lack of immunosuppression accumulation or need for laboratory monitoring. Disclosure statement: P.J.M.: Consultancies: Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Eli Lilly, Novartis, Pfizer, Roche, UCB. Member of speakers' bureau: Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Genentech, Janssen, Eli Lilly, Pfizer, UCB. Grants/research support: Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Eli Lilly, 073 Symptoms in those patients with dactylitis/enthesitis at BL; dactylitis count from 20 digits (score of 0-20) and enthesitis count from six sites (score of 0-6); mixed-effect model repeated measures data from baseline (BL) to week 52.
WHAT SHOULD BE THE PRIMARY TARGET OF TREAT TO TARGET IN PSORIATIC ARTHRITIS?
Laura C. Coates, Paul Emery, Philip G. Conaghan and Philip S. Helliwell Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UNITED KINGDOM Background: Treat to Target (T2T) in SpA Recommendations stated that the target should be remission. The only data in PsA is the Tight Control of PsA (TICOPA) trial which used minimal disease activity (MDA). However MDA is not remission. Potential definitions could be MDA meeting all 7 cut-points [very low disease activity (VLDA)] or Disease Activity in PsA (DAPSA) remission. We investigated which patients achieve these definitions and how much residual disease is present.
Methods: This analysis uses data from the TICOPA study, where 206 PsA patients were randomized to receive either tight control (4 week review using MDA) or standard care. Three potential definitions of remission/inactive disease were used: VLDA, where all seven MDA cut points are met: tender joint count (TJC) 1, swollen joint count (SJC) 1, enthesitis count 1, PASI 1, patient global visual analogue scale (VAS) 20 mm, patient pain VAS 15 and health assessment questionnaire 0.5. DAPSA remission, where
Results: At 48 weeks, 50 patients were in DAPSA remission, 58 in cDAPSA remission and 27 met VLDA. The highest correlation in remission definitions was between DAPSA/cDAPSA (Pearsons 0.927) with lower correlation between both DAPSA/cDAPSA and VLDA (0.609/0.593). The percentage exact agreement for VLDA and DAPSA/cDAPSA remission was 85.2/83.0%. There were 25 people in DAPSA remission and 30 in cDAPSA remission who did not meet VLDA. In contrast, only 2 people were not in DAPSA remission but did meet VLDA. Levels of residual active disease are shown in Table 1 .
Lower disease activity was seen in VLDA, particularly for SJC and enthesitis. All definitions had similar proportions with raised CRP levels despite the CRP not being included in two of the definitions.
075 TABLE 1. Levels of residual active disease 
Conclusion:
The VLDA criteria are more stringent than both DAPSA/ cDAPSA remission, with a lower number of people meeting this definition and less residual disease activity. The inclusion of a laboratory marker seems unnecessary as high CRP levels are similar in all definitions, making assessment easier in clinical practice. Background: Pooled safety data from the psoriasis (PsO) and psoriatic arthritis (PsA) clinical trial programs of secukinumab, through approximately 1 year, have been reported previously. Specifically, the exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) and serious adverse events (SAEs) for PsO and PsA were 252.9 and 7.8 and 210.3 and 9.0 per 100 patient-years, respectively. Here we present updated analyses following additional exposure (with a 25 December 2015 data cut-off), either from a larger study pool (PsO) and/or an extended follow-up period (PsO, PsA). Methods: The updated PsO pool consisted of four Phase II and nine Phase III studies in patients with moderate-to-severe plaque PsO, including two active comparator studies with etanercept and ustekinumab; the PsA pool consisted of two placebo-controlled Phase III studies in patients with active PsA. Secukinumab doses differed in the studies and included intravenous (3-10 mg/kg) or subcutaneous (75-300 mg) loading, followed by subcutaneous maintenance dosing (300, 150, or 75 mg). Placebo patients were re-randomized to secukinumab between 12 and 24 weeks in the various studies. EAIRs were calculated to minimize the impact of between-group differences in treatment exposure. Results: In both the PsO and PsA pools, the most frequently reported AEs with secukinumab were non-serious infections, including nasopharyngitis and upper respiratory tract infection, headache and arthralgia ( Table 1 ). The EAIRs of AEs of special interest with secukinumab, including Crohn's disease, Candida infections, serious infections, neutropenia, major adverse cardiac events, and malignancy, were similar across PsO and PsA studies and comparable to those reported previously (Table 1) . Conclusion: Treatment with secukinumab was well tolerated in PsO and PsA patients. This longer-term safety assessment was consistent with previous reports and did not identify any new safety signals. The long-term safety profile of secukinumab was comparable across PsO and PsA patients, allowing a broader understanding of the safety of secukinumab in these two closely related disease populations. Background: Secukinumab demonstrated higher minimal disease activity (MDA) response rates and sustained improvements in patientreported outcomes among active psoriatic arthritis (PsA) patients through Week 52 in the FUTURE 2 study. This post hoc analysis explores the impact of secukinumab on individual components of MDA and its relationship with patient-reported outcomes through Week 52 of the study. Methods: 397 patients with active PsA were randomized to subcutaneous (s.c) secukinumab (300 mg, 150 mg or 75 mg) or placebo at baseline, Weeks 1, 2, and 3, and every 4 wks (q4w) from Week 4. Patients were considered in MDA when they met at least 5 of 7 pre-defined criteria. The proportion of patients achieving each individual criterion of MDA and the proportion of patients achieving all seven criteria of MDA were calculated at Weeks 24 and 52. Additionally, SF-36 MCS, SF-36 PCS, FACIT-Fatigue, PsAQoL and DLQI were assessed in MDA responders and non-responders at Weeks 24 and 52 using mixed-model for repeated measures (MMRM) analyses. Results: In the pooled secukinumab (300 mg and 150 mg) MDA responder group, tender entheseal points 1 (96%), HAQ-DI 0.5 (95%) and PASI 1 (91%) were the individual components of MDA that consistently achieved the greatest response rates followed by swollen joint count 1 (87%), patient global VAS 20 (87%), tender joint count 1 (80%) and patient pain VAS 15 (78%) at Week 24. A similar trend for the pooled secukinumab MDA responder group was observed at Week 52. Among the MDA responders, 40% (27/68) and 33% (30/93) met all of the seven components at Weeks 24 and 52, respectively in the overall study population. Greater improvements in SF-36 MCS and PCS, PsAQoL, FACIT Fatigue, and DLQI scores were seen among MDA responders compared to non-responders at Weeks 24 and 52 (Table 1) . 076 TABLE 1. Summary of pooled safety across 13 psoriasis and 2 psoriatic arthritis studies (entire safety period) SF-36 MCS 6.9 4.1 6.8 4.4 P < 0.01 P < 0.01 SF-36 PCS 9.0 4.6 9.9 4.6 P < 0.001 P < 0.001 FACIT-Fatigue 9.0 4.9 9.5 5.4 P < 0.001 P < 0.001 PsA QoL À5.2 À3.3 À5.7 À3.4 P < 0.001 P < 0.001 DLQI À9.9 À7.6 À10.7 À8.5 P < 0.01 P < 0.01
Data were pooled across treatment arms. Only subjects with baseline and postbaseline assessment were included. LS means and P-values were derived from MMRM with analysis visit, MDA status at analysis visit and randomization stratum (TNF-a status: naive or inadequate response) as factors; weight and baseline score as continuous covariates and MDA status by analysis visit and baseline score by FACIT.
The individual components most frequently associated with MDA response were related to enthesitis, skin and functional status. A high proportion of patients achieved and maintained their MDA response through Week 52. Achieving MDA with secukinumab was associated with greater patient-reported quality of life outcomes indicating MDA may be a patient-relevant outcome. Background: Psoriatic arthritis (PsA) patients may have significantly compromised physical health and quality of life, and a negative effect on work productivity has been seen. The Work Limitations Questionnaire (WLQ) is a reliable tool for assessing work productivity limitations in patients with chronic health conditions. The WLQ was used in the PALACE 1 (NCT01172938), 2 (NCT01212757) and 3 (NCT01212770) studies, which compared the efficacy and safety of apremilast (APR), an oral phosphodiesterase 4 inhibitor, with placebo in patients with active PsA despite prior conventional diseasemodifying anti-rheumatic drugs and/or biologics. We assessed the effect of APR on work productivity and work limitations over 52 weeks in a pooled analysis of 802 employed patients in PALACE 1-3. Methods: Patients were randomized (1:1:1) to receive placebo, APR 30 mg BID (APR30), or APR 20 mg BID (APR20). Early escape to active treatment was possible at Week 16 for placebo patients; at Week 24, all remaining placebo patients were re-randomized to APR30 or APR20. The WLQ, a 25-item questionnaire assessing the impact of chronic health conditions on work performance and productivity, was administered at baseline, Week 16 and Week 52. Work limitations were categorized into 4 domains: physical demands (PDS), mental demands (MDS), time management demands (TMS), and output demands (ODS). An overall WLQ productivity score is calculated and expressed as the percentage loss in productivity associated with illness. Results: Patient demographics (age, sex, geographic region) were similar across treatment groups for 802 patients who completed !1 domain of the WLQ at baseline. At Week 16, APR30 and APR20 vs. placebo were associated with a greater mean change from baseline in PDS (À2.45 and À1.66 vs. À0.75), MDS (À4.83 and À3.23 vs. 1.29), TMS (À8.03 and À4.64 vs. À0.88) and ODS (À8.26 and À3.97 vs. 0.28), demonstrating improvement from baseline in work productivity loss. Productivity improvements in PDS, MDS, TMS, and ODS were maintained among patients receiving APR30 and APR20 to Week 52 (Table 1) . Conclusion: APR30 and APR20 treatment increased work productivity and improved work limitations among patients in PALACE 1-3. Improvements in work productivity loss were maintained through 52 weeks of treatment.
078. TABLE 1 PALACE 1-3 pooled analysis
Negative changes from baseline indicate improvement. ITT, intention to treat; LOCF, last observation carried forward; NA, not applicable. Background: With the introduction of inflammatory back pain (IBP) criteria to detect early non-radiographic axial spondyloarthritis (SpA), there has been an increase in the number of patients referred to clinics for suspected SpA. Early use of MRI using specific sequences to scan the spine allows detection of non-radiographic axial SpA. Whole spine MRIs has also resulted in increased detection of SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome in patients with IBP. There are characteristic changes in SAPHO on MRI of the spine which together with clinical features distinguishes it from axial SpA. In this study the clinical and radiological features of SAPHO and features distinguishing it from axial SpA are reviewed. Methods: 630 patients presenting with IBP to the Ankylosing Spondylitis (AS) Clinic in a 4 year period (January 2012 to January 2016) were reviewed and investigated for the presence of axial SpA by using the ASAS criteria. Where clinically appropriate, HLA-B27 and whole spine MRIs where requested. Further investigation including isotope bone scan were requested if appropriate. Results: 23 new cases of SAPHO presenting with IBP were detected during this period. The median age was 49 years, with a female predominance (n ¼ 18) versus males (n ¼ 5). The duration of IBP was 2-10 years before diagnosis. All patients had spinal involvement and 18 (78.3%) had anterior chest wall (ACW) involvement, in particular the sternoclavicular and sternocostal joints. Skin involvement was present in 13 (56.5%) and HLA-B27 positivity was low [3 (13%)]. All patients had an initial good response to NSAIDs. MRI of the spine showed extensive inflammatory changes in the thoracolumbar spine and sternocostal joints with bony overgrowth, sclerosis and partial ankylosis (Table 1) . Conclusion: SAPHO syndrome can present with IBP, respond well to NSAIDs and may mimic axial SpA. However, SAPHO is an inflammatory arthropathy distinct from ankylosing spondylitis that should be considered in patients with skin lesions and ACW pain in addition to spinal involvement. The radiological features which distinguish SAPHO from other causes of spinal pain such as SpA and DISH are important for correct management of this group of patients. Background: Despite known safety profile of anti-osteoporosis drugs (AODs) based on randomized controlled trials, recent alerts have demonstrated a need for data on the safety of these drugs in actual practice conditions. We aimed to compare the association between the use of different AODs and the risk of venous thromboembolism (VTE) in patients while on treatment. Methods: A cohort study was conducted including all users of antiosteoporosis medications registered in the CPRD database and in the SIDIAP database. The Clinical Practice Research Datalink (CPRD) and SIDIAP databases contain anonymized primary care records for the UK NHS and for Spain (2006 Spain ( -2014 , respectively. Study exposure was use (as defined by GP prescriptions in CPRD or pharmacy dispensations in SIDIAP) of alendronate (reference group) compared with other oral bisphosphonates and strontium ranelate. Users of denosumab and teriparatide were excluded due to low numbers (n ¼ 29 and n ¼ 7, respectively) in the CPRD database, and users of SERMs were excluded as VTE risk is a formal contraindication for these drugs. Confounders: age, gender, body mass index, smoking, recent fracture/s history, co-morbidities, history of VTE, varicose veins, vein insufficiency, phlebitis and recent use of prothrombotic medications. Outcomes: VTE including deep vein thrombosis and pulmonary embolism. Multiple imputation was used to handle missing data on co-variables, and propensity score matching (PSM) was performed to minimize confounding. A proportional subdistribution hazards regression model was used to estimate the relative risk of VTE [Subhazard ratio (SHR)] with a competing risk of death. A sensitivity analysis was conducted where strontium users were stratified into before/after March 2011, when alerts about a potential increase in VTE risk were published. Results: Data for 161,957 and 127,479 patients were included in the analysis from the CPRD and SIDIAP datasets, respectively. No significant association was found between the included AOD users as compared to users of alendronates in either dataset (Table 1) . Conclusion: We found no evidence of an increased risk of VTE with any of the studied anti-osteoporosis medications compared to alendronate. Residual confounding by indication is possible despite our efforts to minimize related bias. 
Rheumatology and
Director of the MRC Lifecourse Epidemiology Unit, University of Southampton, University of Southampton, Southampton, UNITED KINGDOM Background: Recent concerns have been raised on a possible increase in cardiovascular risk associated with strontium ranelate use. We aimed to compare the association between use of different AODs and the risk of acute myocardial infarction (AMI) among realworld users of AODs in primary care settings. Methods: A cohort study was conducted including all users of antiosteoporosis medications registered in the SIDIAP dataset. The SIDIAP database contains pseudonymized primary care records for a representative >6 million Catalan healthcare system users. Study exposure was use (as defined by GP prescriptions) of alendronate (reference group) compared with other oral bisphosphonates, strontium ranelate and SERMs. Outcomes: Newly recorded AMI while on treatment with any AOD. Multiple imputation was used to handle missing data on co-variables, and propensity score matching (PSM) was performed to minimize confounding. A proportional sub-distribution hazards regression model was used to estimate the relative risk of AMI [Subhazard ratio (SHR)] with a competing risk of death. Confounders for PSM included the available risk factors for AMI: age, gender, body mass index, smoking, drinking, Charlson comorbidity index, chronic kidney failure (based on serum creatinine/ eGFR measures), LDL cholesterol, recent use of systemic glucocorticoids, pro-thrombotic medications (anti-coagulants, hormone replacement therapy), socio-economic status, country of birth, and history of ischaemic heart disease, cerebro-vascular disease, chronic kidney failure, nephrotic syndrome, type 2 diabetes, and recent hip or non-hip fractures. Results: Data for 126,891 patients were included, with a median (interquartile range) follow-up of 5.7 (3.67) years. No significant association was found between the included AOD users as compared to alendronate (Table 1) . Conclusion: We found no evidence of a differential risk of AMI among users of different AODs. Future work will include the replication of these analyses using a similar UK dataset. 081. Background: Physical activity (PA) has previously been shown to be associated with improved musculoskeletal health in later life. Here we investigated patterns of PA impact, divided by level of loading, in older free-living adults, and whether high impact counts were associated with bone microstructure and muscle strength in this population. Methods: We recruited a randomly selected subset of the Hertfordshire Cohort Study (n ¼ 114), a cohort of men and women born 1931-39 who have previously been shown to be representative of the UK population. Subjects wore a tri-axial accelerometer on the waist for 7 days and y-axis peaks were recorded to measure the intensity of weight bearing physical activity. Peaks were classified into low (0.5-1.0g), medium (1.0-1.5g) and high (!1.5g) impact bands. High resolution peripheral quantitative computed tomography (HRpQCT) was performed at distal tibial and radial sites, grip strength was measured by Jamar dynamometer and a lifestyle questionnaire was completed.
Results: Sixty-nine men and 45 women were enrolled with a mean (SD) age of 75.3 (2.6) and 75.4 (2.6) years respectively. The recorded median counts decreased with increasing intensity with 6224 (Interquartile Range:2401-13,232) low intensity counts, 189 (IQR 64-633) medium intensity counts and 38 (IQR 13-112) high intensity counts in this population. Data were analysed unadjusted and then adjusted for gender and BMI. At the radius, low intensity activity counts were positively associated with total area (p < 0.001) and trabecular area (p < 0.001), which remained robust to adjustment. The same pattern was observed for medium intensity counts for total area (p ¼ 0.002) and trabecular area (p ¼ 0.001). We identified a negative association with cortical density (p ¼ 0.011) and this relationship persisted post-adjustment. We identified a positive association between number of high impact counts with total area (p ¼ 0.046) and trabecular area (p ¼ 0.036) though this relationship was attenuated after adjustment. At the tibia, similar, although weaker associations were observed. Spearman's rank demonstrated a significant correlation for increasing grip strength and increasing activity counts at low (Spearman's Rho ¼ 0.33), medium (0.29) and high impact activity (0.17). Conclusion: Our data suggest that low and medium intensity PA are significantly associated with total bone area and trabecular area in older adults. The negative association of medium intensity impact activity with cortical density may be artifactual due to the thinner cortices. There was a positive correlation between grip strength and number of activity counts at all three levels of impact, supporting previous PA data. High impact physical activity rarely occurred in this elderly population. Background: Medication-related osteonecrosis of the jaw (MRONJ) is defined as persistent non-healing exposed dental bone in a patient who has been exposed to an implicated bone-active medication. The patient must also not have metastatic disease or received therapeutic irradiation. The Medicines and Healthcare Products Regulatory Agency (MHRA) advises that all patients with cancer should have a dental check-up before commencing bone-active medications but those commencing for other indications (such as osteoporosis) should undergo additional dental examination only if they have dental problems or other risk factors for MRONJ. Our previous work highlighted the experiences of dental practitioners and rheumatologists in the South-west of England and the rarity of jaw osteonecrosis in the osteoporosis community. We decided to survey clinicians attending the BSR annual conference osteoporosis special interest group (SIG) to explore their experience with MRONJ. Methods: A questionnaire was distributed to attendees of the osteoporosis SIG at the BSR annual conference in April 2016. This explored areas of practice, clinician grade, the number of patients on bone-active medications seen, experience with MRONJ (encounters and management), the existence of local guidelines and the advice given to patients on starting bone prophylaxis. Results: 29 osteoporosis clinicians completed the questionnaire, of which 24 (83%) work in the UK. Despite targeting osteoporosis specialists, 14 (48%) respondents had never seen a case of MRONJ. 64% of those who reported seeing more than 40 patients per month on bone-active medications had encountered a case of MRONJ. Only 7 clinicians (24%) routinely discuss MRONJ on commencing boneactive medications and most [25/29 (86%) ] are unaware of the existence of local or national guidelines regarding the condition. The advice given about dental screening and dental treatment while taking bone-active treatments varies widely among respondents. Less than 30 cases of MRONJ were identified by respondents and most of these gradually healed with conservative or surgical management and there were only 3 reported cases that did not heal of which one had coexistent malignancy (although some cases had been lost to follow-up or were still receiving treatment at the time of responding to the questionnaire). Conclusion: This survey suggests MRONJ is encountered uncommonly, even among those clinicians reviewing relatively large numbers of patients taking bone-active medications. There is a lack of consensus guidelines and practice seems to vary widely in different departments, particularly with regard to dental screening and advice given prior to dental treatment. Locally, a meeting with our dental, oncological and general practitioner colleagues resulted in a prospective database of patients referred for assessment of MRONJ along with direct access appointments to restorative dental colleagues for patients about to start IV bisphosphonates with concurrent malignancy or other significant risk factors for the development of MRONJ. Disclosure statement: The authors have declared no conflicts of interest. Background: The use of anticonvulsant drugs has been associated with a low bone mineral density (BMD) and as a risk factor for fragility fractures in patients (ref) . The FRAX tool uses the femoral neck BMD to predict fractures on a population basis but ignores the lumbar spine. Our objective was to determine the predictors of fragility fractures in an observational cohort of patients on anticonvulsant drugs. Methods: Patients referred for BMD estimation to a scanner in the North West of England between 2004 and 2014 on anticonvulsant drugs were identified from a dual X-ray absorptiometry (DEXA) database. Demographics and other risk factors, as well as fragility fractures, were recorded. Initially, those who had sustained a fracture were compared to those who had not sustained a fracture using chi squared test for categorical variables and t-test for continuous variables. Following that, univariate and multivariate logistic regression models were fitted looking at the predictors of fracture. Variables included age at scan, height, weight, alcohol, smoking, family history, rheumatoid arthritis, secondary osteoporosis as defined by FRAX, body mass index and steroid exposure, in addition to BMD in the lumbar spine and femoral neck. Results: 581 patients were scanned in the referral period. The mean age at scan was 59 (SD 12.78 
THE PREDICTORS OF FRAGILITY FRACTURES IN
ARE WE DOING ENOUGH TO PREVENT FRACTURES IN PATIENTS ADMITTED WITH ALCOHOL-RELATED ILLNESS?
Laura Moyles, Elinor Archer and Clive Kelly Rheumatology and Medicine, Queen Elizabeth Hospital, Gateshead, UNITED KINGDOM Background: A recent report by Public Health England highlighted the growing number of admissions to hospital with alcohol related illness (ARI). One risk associated with increased alcohol intake is osteoporotic fracture, but this is often overlooked in the context of more immediate concerns. There is little work on treatment to prevent fractures in patients who misuse alcohol. The risk of fragility fractures is less understood by both the public and their professionals in comparison to the risk of alcohol liver disease. Methods: A pro forma was developed and administered to patients on medical wards at a single large Hospital over one month. Patients were identified by the alcohol liaison nurses and 50 consecutive admissions as a result of ARI were studied, together with age and sex matched control inpatients admitted for other reasons. Each participant was interviewed by the study team and their medical notes and laboratory results were reviewed. Our aims were threefold:to assess fracture risk using the FRAX tool in patients admitted with ARI, to take a fracture history and calculate the incidence of fragility fracture and to review previous investigations and/or treatment(s) for fragility fracture within this patient group. Results: Of the 50 patients studied, medical intervention was recommended in 29 to reduce fracture risk using the National Osteoporosis Guideline based on FRAX scores. Of these, 22 patients required a DEXA scan to assess bone mineral density (BMD) and 7 had enough risk factors to warrant immediate treatment without a scan. Among 50 patients with ARI, 24 (48%) had experienced a previous fragility fracture but only 2 (4%) had received a DEXA scan and just 14 (28%) were prescribed treatment. This was calcium with vitamin D in 12 and a bisphosphonate in 2. Seven of these patients openly admitted non-compliance with therapy. Conclusion: Patients who misuse alcohol have a higher incidence of fragility fractures. This group of patients appear to be underinvestigated and undertreated. Improvements could be made by reeducating medical staff on the value of the FRAX tool and its relevance in patients with ARI. Background: The treatment of severe osteoporosis can be challenging. Oral monotherapy has been adopted as the gold standard approach, usually using bisphosphonates, but it is unclear how to manage patients who continue to fracture on single agent therapy. Trials of a combination of anabolic agents with oral bisphosphonates have been shown to offer no benefit, but recent studies have reported favourable results from combining parenteral bisphosphonates with an anabolic agent. We report our experience with sequential monotherapy using an anabolic agent to build bone followed by a parenteral bisphosphonate to preserve it. Methods: We identified 19 patients with proven osteoporosis who were all above NOGG treatment thresholds. They [2 male, median age 76 (44-92) years] had sustained a median of 3 (0-7) fractures while on prior monotherapy for a median of 7 months (range 0-19) months. Treatment with anabolic therapy (Teriparatide) was given for 2 years followed by 3 years of annual intravenous Zoledronic acid in all patients. Bone density at the spine, total hip and neck of femur, together with beta-crosslaps to assess bone turnover, were measured at baseline, 2 and 5 years. We calculated changes in these, the number of new fractures occurring over the five year treatment period, serious adverse events and all-cause mortality. Results: All patients had vitamin D levels maintained above 50 nmol/L with normal calcium and PTH levels. Underlying causes for osteoporosis were detected in 13 patients. All patients had taken prior oral bone-active therapy, which had been discontinued due to intolerance (9) or treatment failure (10), combined with falling bone density in all patients. The mean absolute spinal BMD rose from 0.797 (SD 0.16) to 0.880 (SD 0.17) after Teriparatide treatment (p ¼ 0.002) and rose again to 0.895 (SD 0.19) after Zoledronic acid (NS). Similarly significant but less dramatic changes were seen in the total hip and neck of femur. Beta-crosslaps rose from a mean of 246 (SD 193) before Teriparatide to a mean of 890 (SD 695) after Teriparatide therapy (p ¼ 0.004). After Zoledronic acid, they fell to a mean of 154 (SD 51.6), (p ¼ 0.001). There were no new fractures during the five year treatment program in any patient. No serious adverse events from treatment were reported. Two patients died during follow up from their underlying disease. Conclusion: Our results suggest that the use of sequential anabolic therapy for two years followed by annual bisphosphonate infusions for a further three years is both safe and effective in treating patients with recalcitrant osteoporosis who have failed to respond to oral monotherapy. This approach appears effective and well tolerated and may be worth considering in such patients. Disclosure statement: The authors have declared no conflicts of interest.
PREGNANCY-ASSOCIATED OSTEOPOROSIS: A UK CASE SERIES
Fariz Yahya, Sarah A. Hardcastle, Jackie Webb and Ashok K. Bhalla Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UNITED KINGDOM Background: Pregnancy-associated osteoporosis is a rare syndrome affecting women during late pregnancy and in the early post-partum period, which may result in fragility fractures. We describe ten cases of pregnancy-associated osteoporosis from a single UK centre. Methods: Patients had attended the osteoporosis clinic at the Royal National Hospital for Rheumatic Diseases, Bath, between January 2000 and June 2016. The principal inclusion criterion was the occurrence of low trauma fractures either during pregnancy, or up to 18 months post-partum. Data were obtained from retrospective review of medical notes. Bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry (Hologic Discovery system) at the lumbar region of L1-L4 and both hips. Radiographic fractures were further characterized using MRI. Data pertaining to the pregnancy, as well as type and duration of treatment received, were reviewed. Results: The ten cases are summarized in Table 1 . All presented with vertebral fractures, and in all cases Z-scores at the lumbar spine were lower than those at the hip. In four patients, no risk factors for fracture other than pregnancy or breastfeeding could be identified. Four patients were found to have insufficient levels of vitamin D at the time of diagnosis. In addition, two patients had received treatment with low molecular weight heparin (LMWH) which could potentially have contributed to their osteoporosis. In one case, further investigations led to a diagnosis of osteogenesis imperfecta, confirmed on genetic testing. Although her presentation was similar to that of the other cases, the history of several prior fractures during childhood suggested bone loss at a younger age. In terms of treatment, eight out of the ten patients in this series received a bisphosphonate, most commonly risedronate due to its relatively short skeletal retention time. Conclusion: Rheumatologists should be aware of pregnancy-induced osteoporosis, a rare but recognized complication of pregnancy. The condition should be especially considered in women presenting with new onset back pain in pregnancy or the post-partum period. Disclosure statement: The authors have declared no conflicts of interest. Background: Osteoporosis is characterized by a reduced bone density that results in a higher risk of fragility fractures. One in three women and one in five men over the age of 50 will sustain a fragility fracture in their lifetime. Fragility fractures are an important cause of both morbidity and mortality. A recent national survey of 1088 supporters of the National Osteoporosis Society rated easy access to information from health professionals as the top research priority for osteoporosis and fractures out of 40 domains. In order to understand the information needs of patients further, this review aimed to identify information needs expressed by patients with osteoporosis or fragility fractures in published research. Methods: Using terms relating to osteoporosis, fragility fracture and information needs, the following databases were searched: CINAHL, EMBASE MEDLINE, PsychINFO, HMIC, AMED and Web of Science. Papers were also identified using citation tracking. Using predefined inclusion and exclusion criteria, articles were independently screened and quality assessed by two authors. Data were extracted from the studies that were selected for inclusion and a thematic analysis was conducted to draw together findings in a narrative synthesis. Results: The search identified 11,307 articles. Nine empirical studies were included in the review. Patients' information needs identified fell under four groups: understanding the nature of osteoporosis, understanding individual prognosis and outlook, self-management and understanding why (e.g. the purpose of medication and DXA scans). Thematic analysis revealed three overarching themes relating to barriers to information, consequences of having unmet educational needs and suggested solutions. Physician attitudes and relevance of the educational material were identified as important barriers to educational needs being met. Participants described the profound psychosocial impact of having unmet educational needs, as well as broken doctor-patient relationships and poor treatment adherence. Patient participants offered suggestions for ways of addressing information needs, a number of which involved learning from patients themselves.
INFORMATION NEEDS IN PATIENTS PRESENTING
Conclusion: This is the first study to describe the information needs of patients with osteoporosis and fracture and describe not only the areas of information patients feel are lacking, but also the impact of this information gap and possible solutions. Patient involvement in the co-design of future educational materials will ensure that informational needs are addressed and that barriers to information exchange are overcome. Clinicians need to be aware of the importance of information on patient and clinical outcomes. Disclosure statement: The authors have declared no conflicts of interest. Background: There is a growing recognition of the relationship between fat and bone. Relationships between adiposity and fracture appear to be site specific and in general obese individuals tend to have greater bone density. This latter association is partly explained by the presence of adipokines although the precise mechanisms are not fully understood. We explored the associations between serum leptin and adiponectin, and bone health at baseline and longitudinally, in a cohort of older men and women. Methods: 219 men and 178 women were recruited from the Hertfordshire Cohort Study between 1998 and 2003. Demographic and lifestyle factors were obtained through a nurse administered questionnaire. Serum samples were taken and adipokine levels were measured by ELISA. Areal bone mineral density (aBMD) was assessed using a Hologic QDR 4500 and then repeated a mean (SD) of 4.4 (1.0) years later. Relationships were assessed between sex-specific standard deviation (SD) scores of adipokines and bone health parameters using linear regression before and after adjustment for demographic and lifestyle factors. Results: The mean age of participants at baseline was 63.9 (2.5) years in men and 65.8 (2.7) years in women. The median (IQR) for leptin was 9.78 (5.48-21.56) ng/ml and adiponectin was 3.55 (2.11-6.40). In both men and women, lower leptin levels and a higher adiponectin:leptin ratio, were associated with lower femoral neck aBMD. Similar relationships were found with lumbar spine aBMD, with the exception of with leptin in women. These relationships were attenuated after adjustment for age, height, weight for height residual, smoking, alcohol, prudent diet score, and physical activity. No evidence was found of a cross-sectional association between adiponectin and aBMD. Greater percentage loss of lumbar spine aBMD between baseline and follow up was associated with lower baseline adiponectin levels and adiponectin:leptin ratio in men but not women. These relationships were robust to adjustment. Conclusion: These findings provide further evidence of the importance of leptin in bone health. They also demonstrate a potential sexual dimorphism pertaining to the role of adiponectin in determining the rate of bone loss within the spine. Further work is required to replicate these associations and to fully delineate the underlying mechanisms. Background: The bisphosphonates are widely prescribed to treat osteoporosis. They are generally well tolerated, but have a number of recognized side effects, predominantly gastrointestinal. MHRA recommend they are taken in a specific fashion to minimize such side effects and improve efficacy. Several unpredictable side effects related to duration of treatment include a small increased risk of oesophageal cancer, jaw osteonecrosis and atypical femoral fractures. Therefore periodic review of efficacy, side effects and compliance must occur. We sought to examine patient's knowledge around their bisphosphonate medication to support continued informed decision making with regards their treatment. Methods: From November to December 2015, inpatients taking bisphosphonate treatment completed a bespoke questionnaire around their therapy, side effects and treatment duration. Those with cognitive impairment were excluded. Results: 52 patients (23 surgical and 29 medical) completed the questionnaire. The majority took Alendronate. 58% knew their medication was for osteoporosis, and a further 8% reported they took it alongside steroid treatment but didn't understand why. 21% patients recalled some prior counselling or information provision through mixed methods and various health professionals. 71% of patients knew bisphosphonates should be administered differently from other medications, but only 21% were taking it correctly. 25% and 13% had taken bisphosphonates for over five and ten years, respectively, without treatment break or review of on-going appropriateness of therapy. 94% of patients were not aware of any common bisphosphonate side effects and only 17% had dental review prior to commencing therapy. Conclusion: Knowledge around possible side effects is alarmingly low, and although in keeping with other medication studies and inevitably subject to recall bias, we should seek opportunistic means to minimize harm. Patients were on therapy with no planned review or stop date and, in taking bisphosphonates incorrectly, potentially reducing efficacy. Medicines reconciliation at hospital admission is an ideal opportunity for primary care medication review. Inpatient counselling could be provided by prescribing clinicians, specialist nurses or pharmacists with standard practice of re-issuing of patient information leaflets at clinic and inpatient visits. Furthermore, a process facilitating routine bisphosphonate medication review in primary care is necessary but remains challenging. Background: Polymyalgia rheumatica (PMR) and Giant Cell Arteritis (GCA) affect 1-2% of the population aged over 55. There is no current epidemiological evidence about fracture risk in PMR or GCA. The aim of this cohort study was to estimate the incidence rates and relative risk of fragility fracture among patients with PMR and GCA, and the influence of glucocorticoid use on this risk. Methods: Incident cases of PMR or GCA were identified from 1990 to 2004 within the UK primary care dataset (Clinical Practice Research Datalink). Individuals over the age of 40 years, with incident diagnoses of PMR and GCA were identified from 1990 to 2004. For each case, four age-, gender-and GP practice-matched controls were randomly selected. Patients were followed up until the earliest date of: death, transfer out of practice, study end (31 August 2015) or the first fracture. Incidence rates of fragility fracture (defined as hip, vertebral, humerus or radial) per 10,000 person-years were calculated for each disease group and hazard rates were compared to non-PMR/GCA patients using Cox regression models, adjusting for cumulative steroid dose, PPI, bisphosphonate and methotrexate use. Results were further stratified by cumulative glucocorticoid use, using the dose reduction in UK guidelines to calculate typical cumulative dose for PMR (2817.5mg) and GCA (5705mg). Results: 2673 cases of GCA and 12,136 cases of PMR were identified and followed up for a median of 9.13 and 9.27 years, respectively. The incidence rate of fracture was 148.05 (95% CI 141.16, 155.28) per 10,000 person-years for PMR and 147.15 (132.91, 162.91) Background: A previous quality improvement project aiming to improve the safety of intravenous bisphosphonate prescription identified areas for improvement: namely offering drug holidays, completing appropriate baseline investigations and ensuring appropriate follow up. A clinical pro forma was introduced to address these issues. The aim of the current project was to evaluate the service following introduction of the pro forma.
PREDICTING FRACTURES USING BONE MINERAL DENSITY AT DIFFERENT SITES
Methods: The records of patients awaiting bisphosphonate infusions in the next 12 months (2016-17) were collected. Data were obtained from clinical letters, online results and from patient packs kept on the unit. Information was collected on underlying diagnosis, indication, vitamin D and renal function, whether clinical guidelines were adhered to (with respect to clinical indication), duration between infusions and whether drug holidays took place. Results: In total, 48 consecutive patients were identified (89.6% female, 10.4% male): 36 were rheumatology patients, 7 respiratory and 5 endocrinology. The median age was 74.5 . Zoledronate was the only bisphosphonate used. The majority of patients (85%) received IV therapy because of intolerance or GI contraindications. The reason for IV therapy was unclear in 4 patients (9%). The most common underlying diagnoses were rheumatoid arthritis, asthma and polymyalgia rheumatica. Osteoporosis was the most common indication (27 patients), followed by long term steroids (18) and vertebral/hip fractures (10): 21 patients had more than one indication. Clinical guidelines (NICE, RCP or NOGG) were adhered to for 47 patients (with the outlying patient having an underlying diagnosis of hyperparathyroidism). A delay of more than 15 months between infusions was identified in 4 of the patients who received more than one infusion (16%). Of the 10 patients who had received 3 or more infusions, 5 received drug holidays, 4 were high risk on continuous replacement and 1 was identified as potentially eligible for a holiday. Every patient had their eGFR and vitamin D checked prior to infusion. Low vitamin D was identified in 5 patients, who had their infusion delayed until levels were replenished. In 6 patients, eGFR was <50ml/min/1.73m 2 : 4 of these received a reduced dose of bisphosphonate while 2 received the full dose, in variance with local guidelines. Conclusion: The introduction of the pro forma has resulted in an improvement in the standard of care for patients receiving IV bisphosphonates. 100% of patients had appropriate baseline investigations. National guidelines (for indications) were adhered to in the majority of patients and drug holidays were considered appropriately, in line with current practice. The reason for IV therapy was not always clearly documented and some patients had significant delays between infusions. Service developments are planned to address these matters. We can recommend the use of a pro forma to standardize the procedure of delivering bisphosphonate infusions. Disclosure statement: The authors have declared no conflicts of interest.
ANKLE VERSUS WRIST FRACTURE AS A PREDICTOR FOR OSTEOPOROSIS IN PATIENTS <75 YEARS OF AGE
David J. Armstrong and Rhonda E. Hunter Fracture Liaison and Osteoporosis Service, Altnagelvin Hospital, Londonderry, UNITED KINGDOM Background: Wrist fracture is regarded as a typical low trauma fracture and will often lead to referral for investigation for osteoporosis. Ankle fracture, especially following inversion injury and in younger people, is still much less likely to trigger investigation for poor bone health. Methods: We examined the records of 35 consecutive patients with wrist fractures and 35 with ankle fractures between the ages of 50 and 75 attending a Fracture Liaison Service, and compared a range of variables including T scores, vitamin D and BMI. All of the patients had suffered either an inversion fracture of the ankle (malleolar or bimalleolar) or a fracture of the distal radius or ulna in a fall from standing height. None of the patients was already taking a bisphosphonate. Patients were categorized (normal/osteopenia/ osteoporosis) for the T scores at the worst of the two sites (hip or spine) Results: Median age of patients with ankle fracture was 58.2 years compared with 64.6 years in wrist fractures. There was very little difference however between serum vitamin D levels (54.3 v 55.8 nmol/l) or BMI (29.9 v 30.8) in the two groups. Categories of BMD results are shown in Table 1 . Again, there was very little difference between the two groups. The median T score was slightly lower for wrist fracture patients at both lumbar spine (À1.1 v À1.3) and neck of femur (À0.9 v À1.2). Conclusion: Although a small study, we have highlighted that even in younger patients, inversion fracture of the ankle can be a predictor for osteoporosis, and that figures are broadly similar to wrist fractures in the under 75 age group. Fracture liaison services should consider this when arranging case-finding. 095 Background: Use of bisphosphonates is widespread in patients attending rheumatology outpatient departments, both for primary osteoporosis and for prevention and treatment of glucocorticoidinduced osteoporosis (GIO). With recent awareness of the need for regular monitoring of patients taking bisphosphonates and the potential risks from long-term use, we examined the indications, duration and monitoring of bisphosphonate (bp) use in the routine rheumatology outpatient setting. Methods: We examined the records of 470 consecutive review patients attending the rheumatology outpatient department in the Western Health and Social Care Trust (WHSCT) in Northern Ireland. None of these patients was under review purely for osteoporosis (these patients being seen at other clinics) as we wished to focus on the general rheumatology population. Results: 470 consecutive patient records were examined (270 female and 200 male). 62 (13.4%) were prescribed weekly or monthly oral bisphosphonate and 2 six monthly denosumab s/c. Those taking bisphosphonates were significantly older than the group as a whole, (median age 70.5 v 54.8, p < 0.01) and more were female [46/63 (73%) v 270/470 (57%), p ¼ 0.18]. Of the 62 patients using bisphosphonates, 38 were currently taking oral prednisolone (63%), 14 (23%) of whom were taking the steroid for polymyalgia rheumatica. Length of time on bisphosphonates ranged from less than 1 year to more than 12 years. Median duration was 3.0 yrs, with 72% of patients on the drug for less than 5 years, 25% between 5 and 9 years and 3% 10 years or over. 27% of patients taking bp had never undergone a DEXA scan. Of the 73% who had, the median duration of bp use was 2.5 years, as compared with 4.5 years in those who had not. 88% of patients who had never undergone a DEXA scan were prescribed steroid, and the other 12% had been prescribed steroid in the past when the bp was commenced. All PMR patients currently prescribed bp were long term oral steroid users, as compared with less than half of patients with an inflammatory arthritis. Conclusion: Around 13% of unselected rheumatology review patients take regular oral bisphosphonates, and 64% of this group were taking oral corticosteroid. Around a quarter of bp users have never had a DEXA scan. There is a potential gap in monitoring of bp patients who start the drug while prescribed steroids without a DXA and continue it in the longer term without further monitoring, even after the steroid has been withdrawn Disclosure statement: The authors have declared no conflicts of interest. Background: Several studies have shown that, in axial spondyloarthritis (axSpA), smoking is associated with worse disease. However, previous studies are limited in their ability to evaluate any potential dose effects. This study aimed to quantify the effect of smoking status, cessation, and dose, across several disease outcomes. Methods: The BSRBR-AS recruits biologics-naïve ASAS-classification axSpA patients. Data collection includes self-reported smoking status and various measures of disease severity. Multivariable linear models were used to examine the relationship between smoking and disease activity (BASDAI), function (BASFI), metrology (BASMI), spinal pain (VAS), and quality of life (ASQoL). Comparisons were made between ever-versus never-smokers, current versus ex-smokers and heavy vs light smokers. Results: 932 axSpA patients were analysed (71% male, mean age 50yrs) including 19% current smokers, 37% ex-smokers, and 44% never-smokers. Ever-smokers reported a mean BASDAI score >1 unit higher than never-smokers [1.04 (95% CI 0.72, 1.36) ]. Similarly, current smokers reported higher BASDAI than ex-smokers [0.90 (95% CI 0.43, 1.37)]. Worse disease was evident among ever-smokers and current smokers across all five disease markers (see Table 1 ). Heavy smoking (>10 cigarettes per day) was reported by 37%. However, smoking dose was associated with no statistically significant differences in any disease outcome measured (see Table 1 ). Conclusion: This large study of biologics-naïve axSpA patients has demonstrated that smoking is associated with worse disease across a number of disease metrics. Ever-smokers have worse disease than never-smokers and current smokers have worse disease than exsmokers. Every effort should be made to help axSpA patients stop smoking altogether; the data suggest that cutting down (to < 10 cigarettes per day) may not be sufficient to yield improvements in disease outcome. Disclosure statement: The authors have declared no conflicts of interest. Background: Axial spondyloarthritis (SpA) is associated with reduced work productivity and impairment of activities outside work. Biologic therapies have demonstrated a positive impact on work-related outcomes in clinical trials but real world data are limited. We aimed to investigate the prevalence of work disability and activity impairment in patients treated with biologic therapy attending a biologic therapy clinic. Methods: Data were collected from a single-centre, prospective cohort of patients with axial SpA treated with biologic therapy. Standardized outcome measures, including the Work Productivity and Activity Impairment (WPAI) Questionnaire for axial SpA, are collected every 6 months. Data from the most recent clinic visit were analysed using SPSS Statistics 24 (IBM, Armonk, NY, USA). Disease severity measures were compared between employed and unemployed patients using independent samples t-tests. Correlations between work-related outcomes and disease severity measures were investigated using Pearson's correlation. Significance was defined as p < 0.05 with Bonferroni correction. Results: Data were available for 151 patients (mean age 47.6 years, 76% male, 24% current smokers). Mean time since diagnosis was 14.6 years and mean duration of biologic therapy 4.9 years with 14% on a reduced dose regimen. Non-steroidal anti-inflammatory drugs (NSAIDs) were used by 30% of patients. The mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score was 4.0, Ankylosing Spondylitis Quality of Life (ASQoL) 6.4, Bath Ankylosing Spondylitis Global (BAS-G) 3.9 and spinal pain visual analogue scale (VAS) 3.7. WPAI data were provided by 119 patients of whom 71% were employed. Of patients 65 years old, 78% were employed. During the week prior to the last clinic visit, 7/119 patients (5.8%) had missed hours of work due to axial SpA (mean hours missed 15.5). Impairment while working due to axial SpA was reported by 21% and 26% reported impairment of regular daily activities. Significantly higher disease activity scores were seen in the unemployed group compared to the employed group for BASDAI (5.39 vs 3.56, p < 0.05), ASQoL (9.44 vs 5.17), spinal pain VAS (5.27 vs 3.08) and BAS-G (5.69 vs 3.11) (all p 0.004). Statistically significant positive correlations were found between the individual WPAI outcome domains and each of BASDAI, BAS-G, ASQoL and VAS (p 0.001). Conclusion: In this cohort of predominantly working-age patients, the majority of patients are employed and very few patients reported missing hours of work due to axial SpA. However, despite intensive treatment with biologic therapies, an adverse impact on workplace productivity persists. This effect is observed to a greater degree in patients with more severe disease activity and quality of life measures. The impact of disease on employment should be routinely reviewed and opportunities for enhancing work productivity directed towards patients with high disease activity scores. Disclosure statement: D.W.: Other: Janssen, MSD, Pfizer. C.H.: Other: Bristol-Myers Squibb, AbbVie, Chugai, Janssen, Novartis, UCB. C.J.E.: Other: AbbVie, Pfizer, Eli Lilly, Celltrion, Mundipharma, Samsung, Anthera, UCB, Celgene, Roche, Bristol-Myers Squibb, Janssen. T.G.N, P.C., R.A., C.C., B.D., N.H., E.D., R.S. and K.E.W.B. have declared no conflicts of interest. Data presented as mean (95% CI). a Among current smokers, heavy smoking were defined as >10 cigarettes/day; smoking quantity data missing for five participants.
SPONDYLARTHROPATHIES (INCLUDING
HIGH LEVELS OF EMPLOYMENT BUT PERSISTING WORK IMPAIRMENT IN PATIENTS WITH SEVERE AXIAL SPONDYLOARTHRITIS USING BIOLOGIC THERAPIES
IMPROVING THE DIAGNOSTIC RELIABILITY OF MAGNETIC RESONANCE IMAGING FOR SACROILIITIS IN A LONDON DISTRICT GENERAL HOSPITAL
We reviewed the SIJ MRI reports of all patients in our hospital over a 27-month period and the detection rate of sacroiliitis. Furthermore, we investigated the number of MRIs initially reported as normal that were subsequently changed after review by an in-house musculoskeletal (MSK) radiologist. Methods: SIJ MRI reports from February 2014 to June 2016 were collected. All images were re-reviewed by our consultant MSK radiologist who was blinded to the original report. His review was then compared to the formal MRI report at the time. A scan was deemed positive if there was SIJ bone marrow oedema in two contiguous slices on STIR sequence. A 2 population z test was used for the analysis.
Results: 137 patients were included. Mean age was 42.5 years (range 17-83 years) and a female:male ratio was 82:55. 29 MRI scans were initially reported by in-house hospital radiologists and 108 scans by an outsourced provider. In total, 107 patients (79%) were identified as having sacroiliitis on MRI on re-review by our MSK radiologist. Only 29 (21%) patients were identified as having sacroiliitis on the initial report. 18 patients had an equivocal scan that was originally reported as normal, and 12 patients had a normal scan where the report remained unchanged. Of the scans reported internally, 41% of scan reports were consistent with the MSK radiologists report, while 59% of MRIs originally reported as normal were deemed to be abnormal. Of the scans reported externally, only 27% of scan reports were assessed as accurate by the MSK consultant. There was no significant difference between the proportion of MRIs incorrectly reported between internal and external radiologists (p ¼ 0.52). Of the scans originally reported as normal, the proportion incorrectly reported as showing no inflammation was 77% by internal radiologists, and 91.9% by the external radiologists, a difference which neared significance with a p value of 0.052. Conclusion: MRI remains a very sensitive tool in the diagnosis of sacroiliitis. However, interpretation can be difficult. We demonstrated relatively high and comparable rates of incorrect reporting between internal and external general radiologists. Correct reporting seemed to be more accurate among our internal radiologists. This QIP highlighted the importance in ensuring a trained MSK radiologist reviews the MRIs, especially where there is a high degree of suspicion for sacroiliitis. This is particularly important given a delayed diagnosis potentially cause substantial morbidity in a younger patient population. Disclosure statement: The authors have declared no conflicts of interest.
A PROSPECTIVE EVALUATION OF THE DUBLIN UVEITIS EVALUATION TOOL IN UK CLINICAL PRACTICE
Mark Sykes, Louise Hamilton and Karl Gaffney Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UNITED KINGDOM Background: Targeted screening of patients with acute anterior uveitis (AAU), the most common extra-articular manifestation of axial spondyloarthritis (axSpA), may allow earlier treatment of axial disease. The Dublin Uveitis Evaluation Tool (DUET) was developed to direct referral of appropriate AAU patients to rheumatology. The validation exercise reported 96% sensitivity and 97% specificity for axSpA, however limited radiological data were reported. We used MRI to evaluate the performance of the DUET algorithm in a UK population and classified patients according to the Assessment of Spondyloarthritis International Society (ASAS) criteria. Methods: Over a 13 month period consecutive adult patients presenting to the ophthalmology department of a university teaching hospital with AAU and a self-reported history of chronic back pain starting before the age of 45 years were invited to participate. Fiftyseven patients with an existing diagnosis of axSpA were excluded and 76 eligible patients identified. All eligible patients were evaluated clinically and underwent MRI of sacro-iliac joints and thoracolumbar spine. Results: Seventy-three patients completed the study; mean age 48 years, 31.5% HLA-B27 positive, 62% female. Sixteen subjects (22%) had a positive MRI as defined by ASAS. Of the 27 patients classified for referral by the DUET algorithm only 9 (33%) had a positive MRI. A further 7 patients with a final diagnosis of axSpA (positive MRI, HLA-B27 negative, no psoriasis) were classified for discharge by the algorithm. Using MRI outcomes, the sensitivity and specificity of the DUET algorithm in our patient population was calculated at only 56.3% (95% CI 29.9, 80.2) and 68.4% (54.8, 80.1) respectively. Another 12 patients fulfilled the clinical arm of the ASAS criteria, increasing the number of patients classified as axSpA to 28. All of these patients were HLA-B27 positive (as is required by the ASAS clinical criteria) and all would have been referred by the DUET algorithm as HLA-B27 is one of the main referral criteria. Including all patients that fulfill either the imaging or the clinical arm of the ASAS criteria improves the sensitivity of the DUET algorithm to 75% (95% CI 54.8, 88.6) and the specificity to 86.7% (95% CI 72.5, 94.5) in our cohort of patients. Conclusion: Screening tools frequently perform less well outside the original validation cohort. We have shown the DUET algorithm to be a useful tool overall, however, by using HLA-B27 positivity and/or psoriasis as the criteria for referring a patient for further investigation, there is a potential to miss over 40% of patients with radiological axial disease. The algorithm performs better when all cases that fulfill the clinical arm of the ASAS criteria are included. Results: The age range of responders was 18-80; 53% under the age of 55, 56% male, 92% diagnosed as AS, 53% employed, 82% under the care of a rheumatologist, 95% reviewed at least annually. Selfreported scores for axSpA disease severity, pain and fatigue were 5.5, 4.5 and 6 out of 10 respectively. Only 44% were aware of the term axSpA, however 71% of them were not confident of the meaning. Fiftytwo percent were receiving biologic therapy; 63% of these were willing to consider dose tapering if recommended by their rheumatologist. The satisfaction rating for overall care and consultant rheumatologists were 3.7 and 4 out of 5 respectively. Twenty-seven percent reported that this could be improved by being seen promptly during a flare and seeing the same rheumatologist at each visit. Although only 12% had been provided with a written care plan, 55% had discussed this verbally. Thirty-six percent considered that they received all the information they needed about their disease; additional information needs included coping with fatigue (51%), long term prognosis (45%), understanding which symptoms should be investigated (38%), managing flares (38%) and coping with pain (36%). Forty-two percent had been reviewed by a physiotherapist within the last year; of those who had not 42% would like to, and 27% were aware that they could selfrefer to physiotherapy during a flare. Sixty-five percent reported that they were not participating in sufficient regular exercise for their axSpA and general well-being. Conclusion: Although a majority of axSpA patients are under the care of a rheumatologist and express high levels of satisfaction with their care, there are perceived unmet needs including access to information, advice on flare management and access to physiotherapy. NASS would welcome the development of quality standards and individual written care plans for axSpA patients. Disclosure statement: K.G.: Consultancies: AbbVie, Pfizer, Novartis, UCB. Grants/research support: AbbVie, Pfizer, Novartis. S.D., H.P. and D.C. have declared no conflicts of interest.
Gary J. Macfarlane, Maxwell S. Barnish and Gareth T. Jones Epidemiology, University of Aberdeen, Aberdeen, UNITED KINGDOM Background: Some patients with axial spondyloarthritis (axSpA) are recognized clinically to have co-morbid fibromyalgia (FM). However, there are no trials to inform how patients are best managed when axSpA and FM occur together. This study aims to provide data on the frequency of co-occurrence and, among persons with axSpA, to characterize persons with co-morbid FM to inform future trials. Methods: The British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS) has recruited patients with axSpA since December 2012, across 82 centres in Great Britain. All patients recruited are naïve to anti-TNF biologic therapy and are either newly starting such therapy (biologic cohort) or not (non-biologic cohort) and are then followed up for the duration of the study. At recruitment and follow-up, patients complete measures of disease activity and impact, including quality of life, sleep disturbance, fatigue and mood. Clinical information and measurements are recorded. Since September 2015, patients have completed 2011 FM research criteria and, separately, clinicians have confirmed whether they consider the patients to have FM. Results: 886 patients (69% male) were eligible for the current analysis of whom 157 participants (17.7%) met research criteria for FM. Prevalence of FM did not differ according to whether or not a patient met imaging criteria for axSpA. Patients who met FM research criteria reported worse disease activity [BASDAI: mean difference 3.1 (95% CI 2.7, 3.5)], function [BASFI: 3.1 (2.6, 3.5)] and global scores [BAS-G: 3.3 (2.9, 3.8)]. They reported considerably worse Quality of Life (ASQoL difference 7.5 (95% CI 6.6, 8.3); EQ-5D À0.30 (95% CI À0.34, À0.24)] and were significantly more likely to have moderate/severe levels of anxiety (HADS)-anxiety 54.1% v. 16.1%), depression (HADS-depression 42.7% v. 6.9%) and clinically important fatigue (Chalder Fatigue Scale 79.1% v. 32.7%). Absence from work was primarily reported by those who met FM criteria (17% v. 3%), and FM patients also reported their work was impaired around half the time (52% v. 23%). There was, however, no difference in levels of C-reactive protein, extra-spinal manifestations of axSpA (with the exception of a greater swollen joint count) or in history of biologic therapy between those who met and did not meet FM research criteria. Conclusion: Around 1 in 6 patients with axSpA meet research criteria for FM. Those patients have significantly worse markers of disease activity and impact, both on their physical and psychological health. There are no differences, however, in levels of inflammation or most extra-spinal disease manifestations. Developing management approaches that address the unmet needs of axSpA patients with co-morbid FM should be a current research priority. Disclosure statement: G.J.M.: Grants/research support: BSR (who receives funds from AbbVie, Pfizer and UCB). G.T.J.: Grants/research support: BSR (who receives funds from Pfizer, AbbVie and UCB). M.S.B. has declared no conflicts of interest.
CIGARETTE SMOKING AND DISEASE ACTIVITY IN AXIAL SPONDYLITIS: EVIDENCE OF AN EXPOSURE-RESPONSE RELATIONSHIP
Sizheng Zhao, Benjamin Challoner, Mohammed Khattak and Nicola J. Goodson Academic Rheumatology Department, Aintree University Hospital, Liverpool, UNITED KINGDOM Background: Previous cross-sectional studies have shown that a history of ever-smoking in axial spondyloarthritis (axSpA) appears to be associated with more severe disease. The reasons are not well understood. The aim of this study was to explore, in ever-smokers, whether an exposure-response relationship exists between packyears and disease activity in axSpA. Methods: Consecutive patients meeting ASAS criteria for axSpA were recruited. Smoking exposure was recorded in pack-years and categorized into three arbitrary groups ( 10, 11-20, >20 pack-years) with light-smoking ( 10) used as reference. Associations between smoking exposure and) disease activity (BASDAI/ASDAS) and) functional impairment (BASFI) were explored using multivariable linear models, adjusted for age, gender and TNF inhibitor (TNFi) therapy. In addition, ASDAS was divided into four ordinal categories as per ASAS (inactive, moderate, high, and very high disease activity). Difference of ASDAS-category proportions between ever-and non-smokers was assessed using Fisher's exact test. Association between pack-year categories and ordinal ASDAS categories was assessed using multiadjusted ordinal logistic regression. Results: 238 axSpA patients were recruited: 76% were male, mean age 46.4 years (SD 13.7), and 36% were treated with TNFi. 112 (47%) patients reported a history of ever smoking with median pack-year 20 (IQR)10-30, range 0.5-60). ASDAS was available for 188 (79%) patients. Compared to light smokers, those in the highest pack-year category of smoking had significantly higher BASDAI, ASDAS and BASFI scores (Table 1) . Inactive disease (ASDAS<1.3) was found in 22% of non-smokers and 0% of ever-smokers; 18% of non-smokers and 30% of ever-smokers had very severe disease (ASDAS>3.5) (P < 0.001). Those in the heaviest smoking category had over four times greater odds of being in a higher ASDAS category than light smokers [OR adj 4.13 (95%CI 1.01, 17.0)]. Associations with ASDAS were not explained by CRP (data not shown).
Conclusion:
This cross-sectional study demonstrated that smoking is independently associated with increased axSpA severity markers in an exposure-response manner. While it is possible that higher disease activity modifies behaviour and causes increased smoking, the strong exposure-response relationship is more suggestive of a smokingassociated pathological mechanism leading to increased disease activity in axSpA. Particular effort should be made to restrict smoking exposure early before accruing a significant number of pack-years. 105 Results are presented as b coefficient (95% CI). a ASDAS was regressed using complete-case analysis with total sample size n ¼ 89.
Disclosure statement: The authors have declared no conflicts of interest.
IS THERE A SUSTAINED RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITOR DOSE TAPERING IN ANKYLOSING SPONDYLITIS?
Lauren Steel, Max Yates, Louise Hamilton and Karl Gaffney Rheumatology, Norfolk and Norwich University Hospital, Norwich, UNITED KINGDOM
Background: Biologic dose tapering may reduce the risk of side effects in patients receiving treatment, without loss of efficacy, and with considerable cost savings. In the ANSWERS study (ANkylosing Spondylitis With Etanercept RegimeS) patients with active ankylosing spondylitis were treated with standard dose etanercept (ETN) 50mg once weekly for 6 months and those who responded [reduction in both Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and spinal pain visual analogue score (VAS) ! 2 units] were randomized to continue standard therapy or step-down to ETN 25mg once weekly. At 6 months post-randomization, over 50% of participants in the dose tapering arm had maintained their response. However, the long-term efficacy of biologic dose tapering regimes is unknown. In this extension to the ANSWERS study we examined the outcome of dose reduction at 4 years. Methods: Patients in the ETN 25mg arm of the ANSWERS trial who successfully maintained the primary outcome measure (BASDAI reduction !50% or fall ! 2 units and a ! 2 unit reduction in spinal pain as measured on a 10-point scale) at 6 months post-randomization were prospectively evaluated in order to determine whether this response could be maintained in long-term follow-up. Patients who failed to maintain response were then reinstated to ETN 50 mg weekly.
Results: Twelve patients [9 (75%) male, mean age 52 years (SD 14) ] entered the extension study on ETN 25mg once weekly. After a mean follow-up period of 50 months, 4 (33%) patients remained on ETN 25mg. One patient discontinued ETN due to side effects and has remained off biologic therapy. The remaining 7 patients experienced a flare of disease after a mean of 16 months post-randomization and reverted to ETN 50mg weekly. Five patients (71%) recaptured low disease activity within 14 months on standard dose ETN, with two patients switching to another biologic (Humira) because of a loss of efficacy. Conclusion: Although a minority of patients maintained response to the lower dose of ETN over the longer term, the cost savings are substantial -£17,874 per patient at 50 months. Furthermore, the risks 
